A Novel Use of DGKZ Inhibitors

A DGK-zeta inhibitor targets ALDH7A1-deficient cancers, particularly squamous cell carcinoma, by restoring DAG signaling and enhancing immune responses, addressing the limitations of current cancer treatments.

KR1020260161418APending Publication Date: 2026-11-09IND ACADEMIC COOP FOUND YONSEI UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020260078771
Authority / Receiving Office
KR · KR
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-30
Filing Date
2026-04-30
Publication Date
2026-11-09

AI Technical Summary

Technical Problem

Current cancer treatments based on drug targets for genetic mutations are ineffective for many patients, and there is a need for new therapeutic approaches, particularly for squamous cell carcinoma, leveraging synthetic lethality relationships between ALDH7A1 and DGK-zeta to enhance treatment efficacy.

Method used

A pharmaceutical composition utilizing a DGK-zeta inhibitor, such as ASP1570, is developed to target cancers deficient in ALDH7A1, enhancing DAG-dependent signaling pathways and inducing anti-tumor responses, especially in immune checkpoint inhibitor-resistant cancers.

Benefits of technology

The DGK-zeta inhibitor effectively treats ALDH7A1-negative cancers, including squamous cell carcinoma, by restoring DAG-dependent signaling and enhancing immune responses, overcoming resistance to immune checkpoint inhibitors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PAT00001_ABST
    Figure PAT00001_ABST
Patent Text Reader

Abstract

The DGKZ inhibitor provided in the present invention can effectively prevent or treat cancers in which ALDH7A1 expression is suppressed, particularly squamous cell carcinoma. Furthermore, since the DGKZ inhibitor can more effectively prevent or treat cancer in patients with suppressed ALDH7A1 expression, various types of cancer can be effectively prevented or treated by administering the DGKZ inhibitor through the selection or diagnosis of patients for whom it is effective.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a new use of a DGKZ inhibitor.

[0002] This study is a result derived as part of the "Seoul Regional Innovation Center University Support System (RISE)" conducted with funding from the Ministry of Education and the Seoul Metropolitan Government and supported by the Seoul RISE Center in 2026 (2026-RISE-01-022-05). Background Technology

[0003] Cancer ranks among the leading causes of death worldwide. Genetic mutations are known to be fundamental to the development of cancer, and numerous gene mutations that accumulate sequentially in normal cells over long periods lead to the formation of cancer cells that undergo abnormal growth. In some types of cancer, mutations in genes known to play a crucial role in cancer development have been identified, and therapies based on drugs targeting these mutations are already being used in clinical practice. Additionally, drugs based on the mechanisms by which cancer cells evade immune cells have recently shown significant therapeutic effects; however, many cancer patients are still unable to benefit from these treatments.

[0004] Meanwhile, synthetic lethality refers to a relationship between two genes in which cell death occurs only when both genes simultaneously lose their function. Since the 1990s, it has been suggested that this genetic phenomenon could serve as a cornerstone for the development of anticancer treatments. Indeed, following the success of clinical trials based on the synthetic lethality of BRCA1 / 2 and PARP genes, PARP inhibitors are currently being used as treatments for patients with numerous types of cancer possessing BRCA1 / 2 mutations. Therefore, the development of treatments based on new synthetic lethality relationships is expected to make a significant contribution to the discovery of novel cancer inhibitors. The problem to be solved

[0006] One objective of the present invention is to provide a pharmaceutical composition and a treatment method for the prevention or treatment of cancer, particularly squamous cell carcinoma, in which ALDH7A1 expression is suppressed, comprising a diacylglycerol kinase ζ (DGK-zeta) inhibitor as an active ingredient.

[0007] Another objective of the present invention is to provide a method for screening cancer patients, a diagnostic composition, a diagnostic kit, a diagnostic device, and a method for providing information for diagnosis, wherein a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective for cancer prevention or treatment.

[0009] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art from the description below. means of solving the problem

[0011] Various embodiments of the present invention are described with reference to the drawings. In the following description, for a complete understanding of the present invention, various specific details, such as specific forms, compositions, and processes, are described. However, specific embodiments may be practiced without one or more of these specific details, or in combination with other known methods and forms. In other examples, known processes and manufacturing techniques are not described as specific details so as not to make the present invention unnecessary or obscure. Reference throughout this specification to one embodiment implies that a particular feature, form, composition, or characteristic described in association with the embodiment is included in one or more embodiments of the present invention. Accordingly, the circumstances of an embodiment expressed at various locations throughout this specification do not necessarily represent the same embodiment of the present invention. Additionally, a particular feature, form, composition, or characteristic may be combined in any suitable way in one or more embodiments.

[0013] The inventors, through data analysis ALDH7A1 class DGKZ It was discovered that there is a synergistic lethal relationship. Specifically, it was confirmed that lung cancers simultaneously deficient in ALDH7A1 and DGKZ exist rarely at a statistically significant level, and that in such cases, there exist tumor groups in which ALDH7A1 expression is deficient, unlike in normal tissues. Accordingly, it was newly confirmed through various data that treating cancers deficient in ALDH7A1 with ASP1570, a type of DGKZ inhibitor, exhibits anticancer efficacy.

[0014] In particular, it was confirmed that the ALDH7A1 gene, which is one axis of this synthetic lethality relationship, has significantly reduced expression in some tumors of certain cancer types compared to normal tissues (Fig. 1). This frequency was particularly higher in tumors derived from squamous cell carcinoma (LUSC, HNSC, CESC in Fig. 1).

[0016] In one embodiment of the present invention, a pharmaceutical composition for preventing or treating cancer is provided, comprising a diacylglycerol kinase ζ (DGK-zeta) inhibitor as an active ingredient.

[0017] In the present invention, the “diacylglycerol kinase ζ” or “DGK-zeta (Diacylglycerol kinase zeta)” is an enzyme belonging to the diacylglycerol kinase family that mediates the reaction of phosphorylating diacylglycerol (hereinafter DAG) into phosphatidic acid (hereinafter PA) within a cell. This enzyme can regulate DAG-dependent signaling pathways by controlling the intracellular concentration of DAG, and simultaneously induce another signaling mechanism through the generated PA. In particular, DGK-zeta is associated with the regulation of various cellular functions, such as cell growth, migration, survival, and immune responses, and these functions are mainly observed in specialized cell types such as T cells or neurons. Structurally, DGK-zeta contains an ankyrin repeat sequence at its N-terminus, which is involved in protein-protein interactions. Furthermore, it contains a C1 domain for DAG binding, a catalytic domain crucial for enzymatic activity, and a nuclear localization signal (NLS) for nuclear translocation, enabling the regulation of its intracellular location and function. In particular, translocation to the inner membrane or nucleus is known to be one of the major mechanisms regulating DGK-zeta activity both temporally and spatially. The role of DGK-zeta in immune cells, particularly T cells, has been the subject of intensive research; it functions by inhibiting the activity of DAG-dependent signaling molecules such as PKCθ and RasGRP1 by limiting the accumulation of DAG following T cell receptor (TCR) stimulation. This regulation holds significant physiological implications for T cell activation, differentiation, and the maintenance of immune tolerance. Additionally, abnormal expression or function of DGK-zeta has been reported to be associated with various pathophysiological conditions, including autoimmune diseases, cancer, and neurological disorders.Therefore, DGK-zeta acts as a major regulator of DAG / PA metabolic balance and a key regulator of intracellular signaling networks; it has high potential to be utilized as a biomarker or therapeutic target related to immunological regulation, oncological pathways, or neuroscientific mechanisms.

[0018] In the present invention, the “DGK-zeta inhibitor” induces the accumulation of diacylglycerol (DAG) within cells by selectively or non-selectively inhibiting the enzymatic activity of DGK-zeta, thereby exhibiting an action that enhances DAG-dependent signaling pathways. Such inhibitors can be used to restore signaling that is inhibited by excessive activity of DGK-zeta in physiological or pathological situations, or to regulate immune responses and cell survival pathways. DGK-zeta inhibitors are generally based on the following mechanism of action. DGK-zeta is an enzyme that phosphorylates DAG to convert it into phosphatidic acid (PA); if this reaction is blocked, DAG accumulates in the cell membrane. This leads to increased activity of channels such as PKC (Protein Kinase C), RasGRP, and TRPC, which use DAG as a ligand. Consequently, T cell activation, increased cytotoxicity of natural killer (NK) cells, or enhanced growth inhibitory signals within tumor cells may occur. Many of the DGK inhibitors reported to date exhibit non-selective inhibitory activity against the entire DGK family, with representative examples including R59022 and R59949. However, these compounds do not act specifically on DGK-zeta and also affect other isoforms such as DGK-α, which limits their application in biological or therapeutic applications requiring selective inhibition. Consequently, research is currently underway to develop selective inhibitors by targeting the unique structural features of DGK-zeta—e.g., specific binding sites of the C1 domain or ankyrin repeat sequences. The applications of DGK-zeta inhibitors span diverse fields, including immuno-oncology, the regulation of autoimmune diseases, and the modulation of nervous system function.In particular, DGK-zeta inhibitors are attracting attention as pharmacological targets capable of producing synergistic effects when used in combination with immune checkpoint inhibitors in strategies to induce anti-tumor immune responses by inducing T cell de-repression in the tumor microenvironment. Furthermore, their potential as neurological drugs is being raised, with expectations of improving synaptic transmission or memory by regulating DAG metabolism within neurons. Therefore, DGK-zeta inhibitors serve as pharmacological tools that induce the reprogramming of intracellular signaling pathways by regulating the DAG / PA balance, and their specificity, efficacy, cellular permeability, and stability act as key factors determining their future clinical applicability.

[0019] In another embodiment of the present invention, a pharmaceutical composition is provided in which the cancer is an ALDH7A1 negative cancer.

[0020] In the present invention, the “ALDH7A1 negative cancer” refers to a cancer in which the expression or activity of ALDH7A1 is lower than that of a normal control group. The “ALDH7A1 (Aldehyde Dehydrogenase 7 Family Member A1)” is an enzyme protein belonging to the aldehyde dehydrogenase (ALDH) family, which plays an important role primarily in the lysine metabolic pathway and is involved in intracellular metabolic homeostasis and the response to oxidative stress. This enzyme is expressed in various biological tissues, and its activity is particularly high in liver, kidney, and brain tissues. ALDH7A1 plays an essential role in maintaining the stability of pyridoxal 5'-phosphate (PLP), and a deficiency of this enzyme can lead to an imbalance in PLP concentration, causing neurological dysfunction. In particular, loss of function or mutation of the ALDH7A1 gene is known to be a cause of pyridoxine-dependent epilepsy (PDE). This disease is characterized by seizures occurring from the neonatal or early infancy period and features specific clinical characteristics that respond to the administration of pyridoxine (vitamin B6). Specifically, ALDH7A1 mediates the oxidation of α-aminoadipic semialdehyde (AASA) and its derivative, piperideine-6-carboxylate (P6C). Since these intermediates react with PLP to form functionally inactive Schiff bases, a deficiency of ALDH7A1 leads to PLP depletion and consequent inhibition of the biosynthesis of neurotransmitters such as GABA and serotonin. Through this mechanism, ALDH7A1 provides a crucial biochemical basis for maintaining the neurotransmitter system. The structure of ALDH7A1 consists of an NAD(P)+ binding domain, a substrate binding domain, and an oligomerization domain that forms tetramers, exhibiting the structural characteristics of a typical NAD(P)+-dependent dehydrogenase.This enzyme is found not only in the cytoplasm but also in mitochondria, and its expression levels or activity can be regulated depending on the cell's metabolic environment. Recent studies suggest that ALDH7A1 plays functional roles beyond neurological diseases, including defense against oxidative stress, metabolic reprogramming in cancer cells, and regulation of energy metabolism; accordingly, this enzyme is attracting attention as a therapeutic target for various disease states, including neurological disorders, metabolic diseases, and cancer.

[0021] The ALDH7A1 gene encodes an antiquitin protein essential to the lysine metabolic pathway, and mutations or abnormal expression of this gene primarily cause a fatal neurological disorder known as pyridoxine-dependent epilepsy (PDE-ALDH7A1). The core mechanism of this disease involves P6C, an intermediate metabolite of lysine degradation, binding to and inactivating pyridoxal 5-phosphate (PLP), the active form of vitamin B6, thereby leading to a vitamin B6 deficiency in the brain. Consequently, patients exhibit intractable seizures unresponsive to conventional anticonvulsants and symptoms of neonatal encephalopathy. Furthermore, due to the chronic neurotoxicity of metabolites, developmental and intellectual disabilities are commonly associated, particularly manifesting as a delay in language development characterized by a significant decline in expressive language ability compared to receptive language. Structurally, defects in the fetal brain formation process may lead to anatomical abnormalities such as ventriculomegaly, hypoplasia of the corpus callosum, and cerebral atrophy. Folinic Acid-Responsive Seizures (FARS), previously classified as a distinct disorder, have also been identified through genetic analysis as a phenotype of PDE caused by ALDH7A1 mutations. Furthermore, depending on the patient, motor disorders such as dystonia or ataxia may be reported, or behavioral disorders similar to ADHD and the autism spectrum may manifest as neurological signs. Consequently, ALDH7A1 dysfunction forms a group of metabolic neurological disorders that go beyond simple seizures to cause structural and functional degeneration throughout the brain.

[0022] In the present invention, 'metabolic disease' refers to a condition or disease that is closely associated with or caused by obesity, and specifically, it may be one or more selected from the group consisting of fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, and arteriosclerosis.

[0023] In this invention, fatty liver refers to a condition or disease in which fat accumulates in excessive amounts in liver cells due to a disorder of lipid metabolism in the liver.

[0024] In this invention, hyperlipidemia refers to a condition or disease in which the concentration of lipid components in the blood, particularly cholesterol and triglycerides, is higher than normal levels, and is used in a broad sense to include all conditions requiring a reduction in blood lipid concentrations.

[0025] In this specification, arteriosclerosis refers to a condition or disease in which blood circulation to organs and tissues in the body is reduced due to the thickening of artery walls and a decrease in elasticity, and includes the meaning of "atherosclerosis," which refers to a condition or disease in which blood circulation is reduced as the lumen narrows due to the deposition of fat, cholesterol, and other substances on the inner wall of the artery forming plaque. Arteriosclerosis can occur in any part of the body; if it occurs in the blood vessels of the heart, it can cause coronary artery diseases such as angina pectoris and myocardial infarction; if it occurs in the brain, it can cause cerebral infarction; and if it occurs in the kidneys, it can cause renal failure.

[0026] In another embodiment of the present invention, a pharmaceutical composition is provided in which the cancer is an immune checkpoint inhibitor (ICIs) resistant cancer.

[0027] In the present invention, the term "immunological checkpoint inhibitor resistance" refers to a phenomenon in which the response to an immune checkpoint inhibitor decreases or disappears through mechanisms such as being a non-responder group that initially shows no response to the drug, for example, PD-1 inhibitors (pembrolizumab and nivolumab) or PD-L1 inhibitors (atezolizumab), or through which an immune response is induced to recognize the immune checkpoint inhibitor as a foreign substance and eliminate it due to prolonged treatment with the drug.

[0028] In another embodiment of the present invention, a pharmaceutical composition is provided in which the immune checkpoint inhibitor is one or more selected from the group consisting of PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, and TIM-3.

[0029] In the present invention, the term "cancer" refers to or indicates a physiological condition characterized by uncontrolled cell growth typically found in mammals. The cancer subject to prevention, improvement, or treatment in the present invention may be a solid tumor consisting of a mass formed by abnormal cell growth in a solid organ, and may be, for example, gastric cancer, liver cancer, glioblastoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, renal cell carcinoma, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma, or lung cancer depending on the location of the solid organ, and may be, for example, melanoma, but is not limited thereto.

[0030] In another embodiment of the present invention, a pharmaceutical composition is provided in which the cancer is squamous cell cancer.

[0031] In another embodiment of the present invention, a pharmaceutical composition is provided in which the diacylglycerol kinase ζ inhibitor is one or more selected from the group consisting of a small molecule that inhibits diacylglycerol kinase ζ, a diacylglycerol kinase ζ antagonist, an antibody or antigen-binding fragment that specifically binds to diacylglycerol kinase ζ, and an antisense nucleotide that binds complementarily to the transcript sequence of diacylglycerol kinase ζ.

[0032] In the present invention, the “small molecule inhibiting diacylglycerol kinase zeta (hereinafter DGKζ)” has the function of blocking the metabolism of intracellular DAG (diacylglycerol) by inhibiting the activity of the DGKζ enzyme, and consequently activating DAG-based signaling pathways. By restoring or enhancing DAG-dependent signaling pathways (PKC, RasGRP1, etc.), such small molecules can induce physiological effects, such as promoting the activation of immune cells, enhancing anti-tumor responses, or inhibiting the survival of specific pathological cells. Therefore, DGKζ-inhibiting small molecules possess therapeutic potential for various indications, including immune diseases, cancer, and neurological diseases. In addition, preclinical studies have reported that DGKζ inhibition enhances the function of cytotoxic T cells and strengthens antitumor effects when combined with immune checkpoint inhibitors, suggesting that DGKζ inhibitory small molecules can be utilized as adjuvants for tumor immunotherapies. In particular, the importance of DGKζ is being highlighted as a molecular regulatory target within immune cells that induces the recovery of function in CAR-T cells or tumor-infiltrating lymphocytes (TILs).

[0033] In the present invention, the “Diacylglycerol kinase zeta (hereinafter “DGKζ”) antagonist” refers to a pharmacological agent that alters the intracellular lipid metabolic balance by inhibiting the biological activity or inhibiting the function of DGKζ. DGKζ is an enzyme that phosphorylates diacylglycerol (DAG) present in the cell membrane into phosphatidic acid (PA), and plays a central role in the termination of DAG signals and the induction of PA-based signals. DGKζ antagonists inhibit the activity of this enzyme to induce the accumulation of DAG, and consequently exhibit physiological effects that strengthen or restore DAG-dependent signaling pathways (PKC, RasGRP1, TRPC channels, etc.). DGKζ antagonists can directly inhibit DAG phosphorylation by molecularly binding to the substrate binding site or regulatory domain of DGKζ, or indirectly inhibit DGKζ function by affecting the intracellular translocation of the enzyme, protein-protein interactions, or post-translational modifications (e.g., phosphorylation). In particular, since DGKζ contains specific structural domains such as the C1 domain, ankyrin repeat domain, and MARCKS domain, isoform-specific inhibition is possible through antagonists that selectively bind to these sites.

[0034] In the present invention, the “antibody” may be a chimeric antibody, a humanized antibody, a human antibody, a bivalent antibody, a bispecific molecule, a minibody, a domain antibody, a bispecific antibody, an antibody mimic, a unibody, a diabody, a triabody, a tetrabody, or a fragment thereof, but is not limited thereto.

[0035] In the present invention, the term "antibody" refers to a protein molecule that acts as a receptor specifically recognizing an antigen, comprising an immunoglobulin molecule having immunological reactivity with a specific antigen.

[0036] In the present invention, the antibody comprises not only a complete form having two full-length light chains and two full-length heavy chains, but also a functional fragment of the antibody molecule. The functional fragment of the antibody molecule refers to a fragment that possesses at least an antigen-binding function, and includes Fab, F(ab'), F(ab')2, and Fv.

[0037] In the present invention, the antibody may be an antagonist antibody.

[0038] In the present invention, the term “antagonist antibody” refers to an antibody that inhibits biological action or activity within a cell caused by the binding of the antagonist antibody and a ligand by binding to a specific molecule on the cell surface or a specific molecule within the cell.

[0039] In the present invention, the “antigen-binding fragment” comprises, in particular, Fab, F(ab'), F(ab')2, Fv, dAb, Fd, complementarity determining region (CDR) fragment, single-strand antibody (scFv), bivalent single-strand antibody, single-strand phage antibody, unibody, diabody, tribody, tetrabody, polypeptide containing one or more fragments of immunoglobulin sufficient to bind to a specific antigen. The fragment may be produced synthetically, by enzymatic or chemical degradation of complete immunoglobulin, or genetically engineered using recombinant DNA technology. Methods of production are well known in the art.

[0040] In the present invention, the terms "antisense oligonucleotide" or "antisense compound" refer to molecules of RNA, DNA, LNA, PNA, or mixtures thereof that bind to other RNA or DNA (target RNA, DNA). For example, if it is an RNA oligonucleotide, it binds to another RNA target via RNA-RNA interactions and alters the activity of the target RNA. Antisense oligonucleotides can upregulate or downregulate the expression and / or function of specific polynucleotides. This definition is intended to include any foreign RNA or DNA molecules useful from a therapeutic, diagnostic, or other perspective. Such molecules include, for example, antisense RNA or DNA molecules, interfering RNA (RNAi), microRNA, bait RNA molecules, siRNA, enzymatic RNA, therapeutic edit RNA, antisense oligomer compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, primers, probes, and other oligomer compounds that hybridize to at least a portion of the target nucleic acid. Therefore, these compounds can be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.

[0041] In the context of the present invention, the term “oligonucleotide” refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), or a mimic thereof. The term “oligonucleotide” also includes linear or circular oligomers of natural and / or modified monomers or chains, including deoxyribonucleosides, ribonucleosides, their substituted and alpha-anomeric forms, peptide nucleic acids (PNA), locked nucleic acids (LNA), phosphorothioates, methylphosphonates, etc. Oligonucleotides can specifically bind to a target polynucleotide by regular patterns of monomer-monomer interactions, for example, Watson-Crick type base pairing, Hoogsteen or inverse Hoogsteen type base pairing, etc.

[0042] Oligonucleotides can be "chimeras," that is, they can be composed of different regions. In the context of the present invention, a "chimera" compound may be an oligonucleotide having two or more chemical regions, for example, DNA regions, RNA regions, PNA regions, LNA regions, etc.

[0043] Oligonucleotides can be composed of regions that can be connected, either continuously as monomers are in native DNA or through spacers. These spacers are intended to form a shared "bridge" between these regions and, if desired, have a length not exceeding approximately 100 carbon atoms. These spacers may possess different functionalities that induce specific secondary structures, such as, for example, positive or negative charges, specific nucleic acid binding properties (inserts, groove binders, toxins, fluorescent dyes, etc.), lipophilicity, and alanine-containing peptides that induce alpha-helix.

[0044] In this specification, the term “target nucleic acid” encompasses DNA, RNA transcribed from such DNA (including premRNA and mRNA), and cDNA derived from such RNA encoding a non-coding sequence, sense or antisense polynucleotide. Specific hybridization of an oligomeric compound with a target nucleic acid interferes with the normal function of said nucleic acid. Such modulation of the function of said target nucleic acid by a compound that specifically hybridizes to the target nucleic acid is generally referred to as “antisense.” The functions of the DNA that are interfered with include, for example, replication and transcription.

[0045] RNA interference “RNAi” is mediated by double-stranded RNA (dsRNA) molecules having sequence-specific homology to a “target” nucleic acid sequence. In certain embodiments of the present invention, the mediator is a 5- to 25 nucleotide “small interfering” RNA double helix (siRNA). These siRNAs are derived from the processing of dsRNA by an RNase enzyme known as Dicer. The siRNA double helix product is recruited into a multi-protein siRNA complex named RISC (RNA Induced Silencing Complex). Without being limited to any specific theory, RISC is thought to be guided to a target nucleic acid (suitably mRNA), where the siRNA double helix interacts in a sequence-specific manner to mediate cleavage in a catalytic manner. Small interfering RNAs available according to the present invention can be synthesized and utilized according to procedures widely known in the art and familiar to those skilled in the art. The small interfering RNA used in the method of the present invention comprises, suitably, about 1 to about 50 nucleotides (nt). In an example of an unlimited embodiment, the siRNA may comprise about 5 to about 40 nts, about 5 to about 30 nts, about 10 to about 30 nts, about 15 to about 25 nts, or about 20 to 25 nucleotides.

[0046] Techniques for inhibiting gene expression are important tools for the development of therapeutic agents and target validation for disease treatment. Among these techniques, RNA interference (hereinafter referred to as 'RNAi') has been found to act on sequence-specific mRNA in various types of mammalian cells since its role was discovered. When a long strand of RNA double-stranded RNA is delivered to a cell, the delivered RNA double-stranded RNA is converted into small interfering RNA (hereinafter referred to as 'siRNA') by an endonuclease called Dicer, which processes it into 21 to 23 double strands (base pairs, bp). siRNA binds to RISC (RNA-induced silencing complex), and through a process in which the guide (antisense) strand recognizes and degrades the target mRNA, it sequence-specifically inhibits the expression of the target gene.

[0047] That is, in the present invention, “siRNA (small interfering RNA)” is a small RNA fragment of 18 to 23 nucleotides in size produced by cleaving double-stranded RNA by Dicer enzyme, and can be used to inhibit the expression of the corresponding protein or mRNA by specifically binding to mRNA having a complementary sequence.

[0048] The term "nucleotide" includes naturally occurring nucleotides and non-naturally occurring nucleotides. It will be obvious to those skilled in the art that various nucleotides previously considered "non-naturally occurring" are subsequently found in nature. Thus, "nucleotide" includes known purine and pyrimidine heterocyclic-retaining molecules, as well as their heterocyclic analogs and tautomers. Exemplary examples of other types of nucleotides are adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo-N6-methyladenine, 7-deazanthine, 7-deazaguanine, N4, N4-etanocytosine, N6, N6-etano-2,6-diaminopurine, 5-methylcytosine, 5-(C3-C6)-alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridine, isocytosine, isoguanine, inosine, and molecules containing "non-naturally occurring" nucleotides described in Benner et al., US Pat No. 5,432,272.

[0049] The term "nucleotide" may include all of these examples, as well as their analogs and tautomers. Of particular interest are nucleotides possessing adenine, guanine, thymine, cytosine, and uracil, which are considered naturally occurring nucleotides for therapeutic and diagnostic applications in humans. Nucleotides include, for example, naturally occurring 2'-deoxy and 2'-hydroxyl sugars and their analogs, as described in Kornberg and Baker, DNA Replication, 2nd Ed. (Freeman, San Francisco, 1992).

[0050] With respect to nucleotides, "analogs" include synthetic nucleotides possessing modified base moiety and / or modified sugar moiety (e.g., Scheit, Nucleotide Analogs, John Wiley, New York, 1980; Freier & Altmann, (1997) Nucl. Acid. Res., 25(22), 4429-4443, Toulme JJ, (2001) Nature Biotechnology 19:17-18; Manoharan M., (1999) Biochemica et Biophysica Acta 1489:117-139; Freier SM, (1997) Nucleic Acid Research, 25:4429-4443, Uhlman, E., (2000) Drug Discovery & Development, 3: 203-213, Herdewin P., (2000) Antisense & Nucleic Acid Drug Dev., 10:297-310); described generally by 2'-O, 3'-C-linked [3.2.0] bicycloarabinonucleosides). Such analogs include synthetic nucleotides designed to enhance binding properties, e.g., double or triple helix stability, specificity, etc.

[0051] In this specification, "complementarity" refers to the ability of two nucleotides in one or two oligomer strands to form a precise match. For example, if a nucleobase at a certain position of an antisense compound can form a hydrogen bond with a nucleobase at a certain position of a target nucleic acid, and the target nucleic acid is DNA, RNA, or an oligonucleotide molecule, the hydrogen bonding location between the oligonucleotide and the target nucleic acid is considered to be a complementary location. The oligomer compound and additional DNA, RNA, or oligonucleotide molecules are complementary to each other when a sufficient number of complementary locations within each molecule are occupied by nucleotides capable of forming hydrogen bonds with one another. Thus, "specifically hybridizable" and "complementarity" are terms used to indicate a sufficient degree of precise match or complementarity across a sufficient number of nucleotides for a stable and specific bond to occur between the oligomer compound and the target nucleic acid.

[0052] In the field, the sequence of an oligomer compound does not need to be 100% complementary to the sequence of a target nucleic acid in order to hybridize specifically. Additionally, oligonucleotides may hybridize across one or more segments so that intercalation or adjacent segments are not involved in the hybridization phenomenon (e.g., loop structure, mismatch, or hairpin structure). The oligomer compounds of the present invention possess at least approximately 70%, or at least approximately 75%, or at least approximately 80%, or at least approximately 85%, or at least approximately 90%, or at least approximately 95%, or at least approximately 99% sequence complementarity with the target region within the target nucleic acid sequence to which they are targeted. For example, 18 out of 20 nucleotides of an antisense compound are complementary to the target region, and thus the antisense compound that hybridizes specifically will exhibit 90% complementarity. In such examples, the remaining non-complementary nucleotides may be clustered together with the complementary nucleotides, or the complementary nucleotides may be scattered here and there, and they do not need to be adjacent to each other or to the complementary nucleotides. Thus, an antisense compound having a length of 18 nucleotides containing four non-complementary nucleotides that laterally contact two regions of full complementarity with the target nucleic acid will have 77.8% total complementarity with the target nucleic acid and will therefore fall within the scope of the present invention. The ratio of the complementarity of the antisense compound to the region of the target nucleic acid can be determined by using basic local alignment search tools (BLAST) programs and PowerBLAST programs known in the art.Homology, sequence identity, or complementarity ratios can be determined, for example, by the Gap program using default settings (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.) and the algorithm of Smith and Waterman, Adv. Appl. Math., (1981) 2, 482-489.

[0053] The oligonucleotides of the present invention may be any chemical or natural modifications. Chemical and natural modifications are widely known in the relevant art. Such modifications include, for example, modifications designed to increase binding with target strands (i.e., to increase their melting temperature), to assist in the identification of oligonucleotides or oligonucleotide-target complexes, to increase cell penetration, to stabilize against nucleases and other enzymes that degrade or interfere with the structure or activity of oligonucleotides, to provide a termination mode (termination event) when binding to a target in a sequence-specific manner, and to improve the pharmacokinetic properties of oligonucleotides. Modifications include, but are not limited to, (a) terminal modifications, e.g., 5' end modifications (phosphorylation, dephosphorylation, conjugation, inversion linkage, etc.), 3' end modifications (conjugation, DNA nucleotide, inversion linkage, etc.), (b) base modifications, e.g., replacement with a modified base, a stabilizing base, a destabilizing base, or a base that forms a base pair with an extended repertoire of partners, or replacement with a conjugated base, (c) sugar modifications (e.g., at the 2' or 4' position) or sugar replacement, as well as (d) modifications to nucleoside linkages, e.g., modification or replacement of phosphodiester linkages. Modifications may not be optimal for the methods and compositions described herein to the extent that such modifications interfere with translation (i.e., resulting in a 50%, 60%, 70%, 80%, or 90% or greater reduction in translation compared to the absence of modifications, e.g., in in vitro translation assays).Non-limiting examples of modified internucleoside linkages include phosphorothioates, chiral phosphorothioates, phosphodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates having normal 3'-5' linkages, e.g., 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates, e.g., 3'-aminophosphoramidate and aminoalkylphosphoramidate, thionophosphoramidates, thionoalkylphosphorates, thionoalkylphosphotriesters and boranophosphates, their 2'-5' linked analogs, and those having inverted polarity in which adjacent pairs of nucleoside units are linked from 3'-5' to 5'-3' or from 2'-5' to 5'-2'. Various salts, mixed salts, and free acid forms are also included. In some embodiments, the modified oligonucleotide is a single-stranded modified oligonucleotide. In some embodiments, the single-stranded modified oligonucleotide consists of 10⁻³⁰, 10⁻³⁵, 10⁻⁴⁰, 10⁻⁴⁵, 10⁻⁵, 10⁻⁶⁰, 10⁻⁴⁰, 10⁻¹⁰ In some embodiments, the gap segment consists of 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 2-20, 2-30, 2-40, 2-50, 10-20, 10-30, 10-40, or 10-50 linked deoxynucleosides. The 5' wing segment corresponds to a linked nucleic acid (e.g., nucleoside) extending from the 5'-end of the modified oligonucleotide to the nucleic acid preceding the first nucleic acid at the 5'-end of the gap segment.The 3' wing segment corresponds to the nucleic acid (e.g., nucleoside) connected from the last nucleic acid at the 3' end of the gap segment to the last nucleic acid at the 3' end of the modified oligonucleotide. The gap segment is located between the 5' wing segment and the 3' wing segment. In some embodiments, at least one nucleoside of the 5' wing segment and / or at least one nucleoside of the 3' wing segment comprises the modified nucleoside. In some embodiments, the internucleoside linkages within the gap segment and the linkages connecting the gap segment to the 3' wing segment and / or the 5' wing segment are all phosphothioate linkages (*). In some embodiments, the internucleoside linkages connecting the remaining nucleosides of both the 5' and 3' wing segments are phosphodiester linkages. In some embodiments, the nucleosides in the modified oligonucleotide are modified with 2' O-methyl groups. The nucleosides in the modified oligonucleosides may also be modified by any other modifications described herein. In some embodiments, the nucleobase sequence of the modified oligonucleotides consists of 10-30, 10-35, 10-40, 10-45, 10-50, 10-60, 10-70, 10-80, 10-90, 10-100, or more than 100 linked nucleosides and has a salt that is restrictively acceptable thereto. The modified nucleoside linkages that do not contain phosphorus atoms therein have nucleoside linkages formed by linkages between short-chain alkyl or cycloalkyl nucleosides, mixed heteroatoms, and linkages between alkyl or cycloalkyl nucleosides, or linkages between one or more short-chain heteroatoms or heterocyclic nucleosides.These include those having morpholino linkages (partially formed from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide, and sulfone backbones; formacetyl and thioformacetyl backbones; methyleneformacetyl and thioformacetyl backbones; alkene-containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S, and CH2 component portions. The substituted sugar moiety includes, but is not limited to, one of the following at the 2' position: H (deoxyribose); OH (ribose); F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S-, or N-alkynyl; or O-alkyl- O-alkyl (wherein alkyl, alkenyl and alkynyl are substituted or unsubstituted C1 to C. 10 alkyl or C2 to C 1O(It may be alkenyl and alkynyl). Chemically or naturally modified oligonucleotides may comprise, for example, at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-O-alkyl, 2'-O-alkyl-O-alkyl, or 2'-fluoro-modified nucleotide or a terminal cap. In other embodiments, RNA modifications include 2'-fluoro, 2'-amino, and 2'-O-methyl modifications on the ribose of the pyrimidine, a nonbasic residue, or an inversion base at the 3' end of the RNA. An oligonucleotide useful according to the present invention may comprise a single modified nucleoside. In other embodiments, the oligonucleotide may comprise at least two modified nucleosides, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least fifteen, at least twenty or more modified nucleosides up to the entire length of the oligonucleotide. Nucleosides or nucleobases include natural purine bases adenine (A) and guanine (G), and pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleosides are derived from other synthetic and natural nucleobases, such as inosine, xanthine, hypoxanthine, nubularin, isoguanisine, tubercidine, 2-(halo)adenine, 2-(alkyl)adenine, 2-(propyl)adenine, 2-(amino)adenine, 2-(aminoalkyl)adenine, 2-(aminopropyl)adenine, 2-(methylthio)N6(isopentenyl)adenine, 6-(alkyl)adenine, 6-(methyl)adenine, 7-(deaza)adenine, 8-(alkenyl)adenine, 8-(alkyl)adenine, 8-(alkynyl)adenine, 8-(amino)adenine, 8-(halo)adenine, 8-(hydroxyl)adenine, 8-(thioalkyl)adenine, 8-(thiol)adenine, N6-(isopentyl)adenine, N6 (methyl)adenine, N6, N6 (dimethyl)adenine, 2-(alkyl)guanine, 2 (propyl)guanine, 6-(alkyl)guanine, 6 (methyl)guanine, 7 (alkyl)guanine, 7 (methyl)guanine, 7 (deaza)guanine, 8 (alkyl)guanine,8-(alkenyl)guanine, 8-(alkynyl)guanine, 8-(amino)guanine, 8-(halo)guanine, 8-(hydroxyl)guanine, 8-(thioalkyl)guanine, 8-(thiol)guanine, N-(methyl)guanine, 2-(thio)cytosine, 3-(deaza) 5-(aza)cytosine, 3-(alkyl)cytosine, 3-(methyl)cytosine, 5-(alkyl)cytosine, 5-(alkynyl)cytosine, 5-(halo)cytosine, 5-(methyl)cytosine, 5-(propynyl)cytosine, 5-(propynyl)cytosine, 5-(trifluoromethyl)cytosine, 6-(azo)cytosine, N-(acetyl)cytosine, 3-(3-amino-3-carboxypropyl)uracil, 2-(thio)uracil, 5 (methyl) 2 (thio)uracil, 5 (methylaminomethyl)-2 (thio)uracil, 4-(thio)uracil, 5 (methyl) 4 (thio)uracil, 5 (methylaminomethyl)-4 (thio)uracil, 5 (methyl) 2,4 (dthio)uracil, 5 (methylaminomethyl)-2,4 (dthio)uracil, 5 (2-aminopropyl)uracil, 5-(alkyl)uracil, 5-(alkynyl)uracil, 5-(allylamino)uracil, 5 (aminoallyl)uracil, 5 (aminoalkyl)uracil, 5 (guanidiniumalkyl)uracil, 5 (1,3-diazol-1-alkyl)uracil, 5-(cyanoalkyl)uracil, 5-(dialkylaminoalkyl)uracil, 5-(dimethylaminoalkyl)uracil, 5-(halo)uracil, 5-(methoxy)uracil, uracil-5 oxyacetic acid, 5(methoxycarbonylmethyl)-2-(thio)uracil, 5(methoxycarbonyl-methyl)uracil, 5(propynyl)uracil, 5(propynyl)uracil, 5(trifluoromethyl)uracil, 6(azo)uracil, dihydrouracil, N3 (methyl)uracil, 5-uracil (i.e., pseudouracil), 2 (thio)pseudouracil, 4 (thio)pseudouracil, 2,4-(dithio)pseudouracil, 5-(alkyl)pseudouracil, 5-(methyl)pseudouracil, 5-(alkyl)-2-(thio)pseudouracil, 5-(methyl)-2-(thio)pseudouracil, 5-(alkyl)-4 (thio)pseudouracil, 5-(methyl)-4 (thio)pseudouracil, 5-(alkyl)-2,4 (dithio)pseudouracil, 5-(methyl)-2,4 (dithio)pseudouracil, 1-substituted pseudouracil,1 substituted 2(thio)-pseudouracil, 1 substituted 4(thio)pseudouracil, 1 substituted 2,4-(dithio)pseudouracil, 1 (aminocarbonylethylenyl)-pseudouracil, 1 (aminocarbonylethylenyl)-2(thio)-pseudouracil, 1 (aminocarbonylethylenyl)-4(thio)pseudouracil, 1 aminocarbonylethylenyl)-2,4-(dithio)pseudouracil, 1 (aminoalkylaminocarbonylethylenyl)-pseudouracil, 1 (aminoalkylamino-carbonylethylenyl)-2(thio)-pseudouracil, 1(aminoalkylaminocarbonylethylenyl)-4(thio)pseudouracil, 1 (aminoalkylaminocarbonylethylenyl)-2,4-(dithio)pseudouracil, 1,3-(diaza)-2-(oxo)-phenoxazine-1-yl, 1-(aza)-2-(thio)-3-(aza)-phenoxazine-1-yl, 1,3-(diaza)-2-(oxo)-phenthiazine-1-yl, 1-(aza)-2-(thio)-3-(aza)-phenthiazine-1-yl, 7-substituted 1,3-(diaza)-2-(oxo)-phenoxazine-1-yl, 7-substituted 1-(aza)-2-(thio)-3-(aza)-phenoxazine-1-yl, 7-substituted 1,3-(diaza)-2-(oxo)-phenthiazine-1-yl, 7-substituted 1-(aza)-2-(thio)-3-(aza)-phenthiazine-1-yl, 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazine-1-yl, 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazine-1-yl, 7-(aminoalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenthiazine-1-yl, 7-(aminoalkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazine-1-yl, 7-(guanidiniumalkylhydroxy)-1,3-(diaza)-2-(oxo)-phenoxazine-1-yl, 7-(guanidinium alkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenoxazine-1-yl, 7-(guanidinium alkyl-hydroxy)-1,3-(diaza)-2-(oxo)-phenthiazine-1-yl, 7-(guanidinium alkylhydroxy)-1-(aza)-2-(thio)-3-(aza)-phenthiazine-1-yl, 1,3,5-(triaz)-2,6-(dioxa)-naphthalene, inosine, xanthine, hypoxanthine, nubularin, tubercidine, isoguanisine, inosinyl,2-Aza-inosinyl, 7-Deaza-inosinyl, Nitroimidazolyl, Nitropyrazolyl, Nitrobenzimidazolyl, Nitroindazolyl, Aminoindolyl, Pyrrolopyrimidinyl, 3-(methyl)isocarbostirillyl, 5-(methyl)isocarbostirillyl, 3-(methyl)-7-(propynyl)isocarbostirillyl, 7-(Aza)indolyl, 6-(methyl)-7-(Aza)indolyl, Imidazopyridinyl, 9-(methyl)-Imidazopyridinyl, Pyrrolopyrimidyl, Isocarbostirillyl, 7-(propynyl)isocarbostirillyl, Propynyl-7-(Aza)indolyl, 2,4,5-(trimethyl)phenyl, 4-(methyl)indolyl, 4,6-(dimethyl)indolyl, phenyl, naphthalenyl, anthracenyl, phenanthracenyl, pyrenyl, stilbenyl, tetracenyl, pentacenyl, difluorotolyl, 4-(fluoro)-6-(methyl)benzimidazole, 4-(methyl)benzimidazole, 6-(azo)thymine, 2-pyridinone, 5-nitroindole, 3-nitropyrrole, 6-(aza)pyrimidine, 2-(amino)purine, 2,6-(diamino)purine, 5-substituted pyrimidine, N2-substituted purine, N6-substituted purine, O6-substituted purine, substituted 1,2,4-triazole, pyrrolo-pyrimidine-2-one-3-yl, 6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, Para-substituted-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, ortho-substituted-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, bis-ortho-substituted-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, para-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, bis-ortho-(aminoalkylhydroxy)-6-phenyl-pyrrolo-pyrimidine-2-one-3-yl, pyridopyrimidin-3-yl, 2-oxo-7-amino-pyridopyrimidin-3-yl, 2-oxo-pyridopyrimidin-3-yl, or any of these. It includes O-alkylated or N-alkylated derivatives. The antisense oligonucleotide of the present invention may be a chimeric oligonucleotide. The chimeric antisense compound of the present invention includes two or more of the oligonucleotides described above, modified oligonucleotides,It may be formed into a complex structure of an oligonucleotide and / or an oligonucleotide mimic. Such compounds have also been referred to in the art as hybrid or mixed backbone, chimera, or gapmer. In particular, a gapmer is an oligonucleotide having at least three distinct parts, two of which are similar, i.e., containing one or more backbone modifications, and surround a distinct (i.e. not included in the backbone modification) region. The oligonucleotide may contain molecular species at one or both ends, i.e., at the 3' and / or 5' ends. As used herein, molecular species refers to any compound that is not a naturally occurring or non-naturally occurring nucleotide. Molecular species include spacers, lipids, sterols, lipid moiety, e.g., cholesterol moiety, cholic acid, thioethers, e.g., hexyl-S-tritylthiol, thiocholesterol, aliphatic chains, e.g., dodecanediol or undecyl residues, phospholipids, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, polyamine or polyethylene glycol chains, or adamantane acetic acid, palmityl moiety, octadecylamine or hexylamino-carbonyl-oxycholesterol moiety, stearyl, C16 alkyl chains, bile acids, cholic acid, taurocholic acid, deoxycholate, oleyl lithocholic acid, oleoylcholenic acid, glycolipids, phospholipids, sphingolipids, isoprenoids, e.g., steroids, vitamins, e.g., vitamin E, saturated Fatty acids, unsaturated fatty acids, fatty acid esters, e.g., triglycerides, pyrene, porphyrin, texaphyrin, adamantan, acridin, biotin, coumarin, fluorescein, rhodamine, Texas-Red, digoxigenin, dimethoxytrityl, t-butyldimethylsilyl, t-butyldiphenylsilyl, cyanine dyes (e.g., Cy3 or Cy576), Hoechst 33258 dyes, psoralen, or ibuprofen are included, but not limited thereto.

[0054] In another embodiment of the present invention, a pharmaceutical composition is provided in which the small molecule inhibiting diacylglycerol kinase ζ is one or more selected from the group consisting of ASP1570, Veludacigib (BAY 29665501), and DGKζ-IN-3 (CAS No. : 2732901-70-9). The small molecule inhibiting diacylglycerol kinase ζ is not particularly limited as long as it can inhibit diacylglycerol kinase ζ.

[0055] In another embodiment of the present invention, a pharmaceutical composition is provided in which an antisense nucleotide that binds complementarily to the transcript sequence of the diacylglycerol kinase ζ is one or more selected from the group consisting of short interfering RNA (siRNA), microRNA (miRNA), short hairpin RNA and ribozyme, dsNRA, aptamer, PNA (peptide nucleic acid), ZFN, TALEN and CRISPR (cluster regularly interspaced short palindromic repeats) related nucleic acid, single guide RNA (sgRNA), CRISPR-RNA (crRNA), and trans-activated crRNA (tracrRNA).

[0057] In one embodiment of the present invention, a method for selecting cancer patients is provided in which a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective for cancer prevention or treatment.

[0058] In another embodiment of the present invention, a method for screening cancer patients is provided, wherein the cancer is ALDH7A1 negative or DGK negative cancer.

[0059] In one embodiment of the present invention, a composition for diagnosing cancer patients effective with a diacylglycerol kinase ζ (DGK-zeta) inhibitor is provided, comprising a fragment of ALDH7A1 or DGK protein; or a preparation for measuring the expression level of a gene encoding the same.

[0060] In another embodiment of the present invention, a diagnostic composition is provided in which the cancer is an ALDH7A1 negative or DGK negative cancer.

[0061] In another embodiment of the present invention, a diagnostic composition is provided, wherein a preparation for measuring the expression level of the protein comprises one or more selected from the group consisting of antibodies, oligopeptides, ligands, PNA (peptide nucleic acid), and aptamers that specifically bind to the protein.

[0062] In another embodiment of the present invention, a diagnostic composition is provided, wherein a preparation for measuring the expression level of the gene comprises one or more selected from the group consisting of primers, probes, and antisense nucleotides that specifically bind to the gene.

[0063] In another embodiment of the present invention, a diagnostic composition is provided, the composition being intended for application to a biological sample isolated from a target individual.

[0064] In another embodiment of the present invention, the biological sample is whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate A diagnostic composition is provided comprising one or more selected from the group consisting of aspirate, organ secretions, cell, cell extract, and cerebrospinal fluid.

[0065] In one embodiment of the present invention, a diagnostic kit comprising the above diagnostic composition is provided.

[0066] In another embodiment of the present invention, a diagnostic kit is provided, wherein the kit is an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or a Multiple Reaction Monitoring (MRM) kit.

[0067] In one embodiment of the present invention, a method for providing information for diagnosing cancer patients in which a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective is provided, comprising: a step of measuring the expression level of a fragment of ALDH7A1 or DGK protein; or a gene encoding therethese, in a biological sample isolated from a target individual; and a step of determining that a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective if the expression level of the ALDH7A1 or DGK protein fragment; or the gene encoding therethese measured in the biological sample is lower than that of a control group.

[0068] In one embodiment of the present invention, a diagnostic device for a cancer patient is provided, comprising: (a) a step of measuring the expression level of a fragment of ALDH7A1 protein or a gene encoding it in a biological sample isolated from a target individual; a measuring unit for measuring the expression level of the fragment of ALDH7A1 protein or the gene encoding it measured in the biological sample; and (b) a detection unit for outputting whether a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective in a cancer patient from the expression level of the gene or the protein encoded by it measured by the measuring unit.

[0070] In the present invention, "prevention" or "improvement" may include, without limitation, any act of blocking, suppressing, or delaying the symptoms of a disease using the pharmaceutical composition of the present invention.

[0071] In addition, in the present invention, "treatment" may be included without limitation as long as it is any act that improves or benefits the symptoms of a disease using the pharmaceutical composition of the present invention.

[0072] In the present invention, the pharmaceutical composition may be characterized in that it is in the form of a capsule, tablet, granule, injection, ointment, powder, or beverage, and the pharmaceutical composition may be characterized in that it is intended for humans.

[0073] In the present invention, the pharmaceutical composition is not limited to these but may be formulated and used in the form of oral formulations such as powders, granules, capsules, tablets, and aqueous suspensions, as well as topical preparations, suppositories, and sterile injectable solutions, according to conventional methods. The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. For oral administration, the pharmaceutically acceptable carrier may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, colorants, flavorings, etc. For injectable preparations, it may include buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, etc., in a mixed form; and for topical administration, it may include bases, excipients, lubricants, preservatives, etc. The formulations of the pharmaceutical composition of the present invention may be prepared in various ways by mixing with the pharmaceutically acceptable carriers described above. For example, for oral administration, it can be manufactured in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and for injectables, it can be manufactured in the form of unit ampoules or multiple doses. In addition, it can be formulated into solutions, suspensions, tablets, capsules, sustained-release formulations, etc.

[0074] Meanwhile, examples of carriers, excipients, and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil. Additionally, fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, etc. may be additionally included.

[0075] The routes of administration of the pharmaceutical composition of the present invention are not limited to but include oral, intravenous, intramuscular, intra-arterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual, or rectal. Oral or parenteral administration is preferred.

[0076] In the present invention, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intradural, intralesional, and intracranial injection or infusion techniques. The pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.

[0077] The pharmaceutical composition of the present invention may vary depending on several factors including the activity of the specific compound used, age, body weight, general health, gender, diet, time of administration, route of administration, elimination rate, drug combination, and the severity of the specific disease to be prevented or treated, and the dosage of the pharmaceutical composition may be appropriately selected by a person skilled in the art, depending on the patient's condition, body weight, degree of disease, form of medication, route of administration, and duration, and may be administered at a dose of 0.0001 to 50 mg / kg or 0.001 to 50 mg / kg per day. Administration may be administered once a day or divided into several doses. The dosage does not limit the scope of the present invention in any way. The pharmaceutical composition according to the present invention may be formulated as a pill, coated tablet, capsule, liquid, gel, syrup, slurry, or suspension.

[0078] The food composition of the present invention can be manufactured in the form of various food products, for example, beverages, chewing gum, tea, vitamin complexes, powders, granules, tablets, capsules, confectionery, rice cakes, bread, etc.

[0079] In the present invention, when the active ingredient is included in a food composition, the amount may be added in a ratio of 0.1 to 50% of the total weight, but is not limited thereto.

[0080] In the present invention, when the food composition is prepared in the form of a beverage, there are no special limitations other than including the food composition in the indicated proportions, and it may contain various flavoring agents or natural carbohydrates as additional ingredients, as in conventional beverages. Specifically, as natural carbohydrates, it may include monosaccharides such as glucose, disaccharides such as fructose, polysaccharides such as sucrose, conventional sugars such as dextrin, cyclodextrin, etc., and sugar alcohols such as xylitol, sorbitol, erythritol, etc. As the flavoring agent, it may be a natural flavoring agent (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.)) and a synthetic flavoring agent (saccharin, aspartame, etc.).

[0081] In the present invention, the food composition may further include various nutritional agents, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc.

[0082] In the present invention, the above components may be used independently or in combination. Although the proportion of the above additives does not constitute a core element of the present invention, it may be selected in the range of 0.1 to about 50 parts by weight per 100 parts by weight of the food composition of the present invention, but is not limited thereto. Effects of the invention

[0084] The DGKZ inhibitor provided in the present invention can effectively prevent or treat cancer in which the expression of ALDH7A1 is suppressed, particularly squamous cell carcinoma. In addition, since the DGKZ inhibitor can more effectively prevent or treat cancer in patients in whom the expression of ALDH7A1 is suppressed, various types of cancer can be effectively prevented or treated by administering the DGKZ inhibitor by selecting or diagnosing patients for whom the DGKZ inhibitor is effective. Brief explanation of the drawing

[0086] Figure 1 shows the results of confirming ALDH7A1 gene expression in tumor and normal tissues of five cancer types using TCGA (The Cancer Genome Atlas) data from GEPIA (http: / / gepia.cancer-pku.cn / ). The cancer types are as follows: BLCA: Bladder Urothelial Carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, ESCA: Esophageal carcinoma, HNSC: Head and Neck squamous cell carcinoma, LUSC: Lung squamous cell carcinoma. Figure 2a shows the TCGA transcriptome data. It was confirmed that the expression of ALDH7A1 was divided into overexpression and underexpression groups in head and neck cancer (HNSC), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), bladder urothelial carcinoma (BLCA), and lung squamous cell carcinoma (LUSC) tumors. Figure 2b shows CCLE data. It was confirmed that cancer cells lacking both ALDH7A1 and DGKZ genes were significantly rare. Figure 3a is a heatmap of ALDH7A1 and DGKZ expression in lung cancer, head and neck cancer and cervical cancer cell lines using CCLE proteomics or transcriptomics data. FIGS. 3b to 3c ALDH7A1This is a comparison of the anticancer efficacy of the drug ASP1570 in human lung cancer, cervical cancer, and head and neck cancer cell lines that are deficient or expressing. Specifically, Figure 3b shows the drug concentration response curves of ASP1570 by cell line, and Figure 3c shows the survival rates of each cell line compared to the control group (DMSO) at a concentration of 3.17 μM. Cell lines colored in red are deficient in ALDH7A1, and error bars represent the standard error. Figure 3d shows the changes in cells after treating ALDH7A1-deficient HCC95 with ASP1570. As a result, it was confirmed that the cancer cells became loosely attached to the surface of the culture plate and changed into a round shape, and the F-actin signal decreased. Fig. 3e ALDH7A1 This is the result of comparing the anticancer efficacy of the drug ASP1570 in human head and neck cancer cell lines that are deficient or expressing it. (Left) ALDH7A1 protein expression in human head and neck cancer cell lines. The expression of each protein was confirmed by Western blot using antibodies against ALDH7A1 (Abcam, 68192, 1:1,000) and β-actin (Cell Signaling Technology, 4970, 1:1,000). (Right) Survival rates relative to the vehicle (DMSO) for each cell line at ASP1570 concentrations of 0 μM or 3.17 μM. Error bars represent the standard error. Figure 4a shows the results of constructing HCC95 cell lines with an empty vector or ALDH7A1 overexpression (ALDH7A1-OE). The expression of each protein was confirmed by Western blot using antibodies for ALDH7A1 (abcam, 68192, 1:1,000) and β-actin (Cell Signaling Technology, 4970, 1:1,000). Fig. 4b is ALDH7A1 This is the result of analyzing the adhesion and growth patterns of cancer cells after treatment with ASP1570 in overexpressing (ALDH7A1-OE) HCC95 cell lines. As a result, it was confirmed that the anticancer efficacy of ASP1570 significantly disappeared. Figure 5a shows wild (sgNT) or HCC78 human lung cancer cells. ALDH7A1 This is the result of constructing knockout (sgALDH7A1-1, sgALDH7A1-3) cell lines. Specifically, the expression of each protein was confirmed by Western blot using antibodies for ALDH7A1 (abcam, 68192, 1:1,000) and β-actin (Cell Signaling Technology, 4970, 1:1,000). Figure 5b shows wild (sgNT) or CT-26 mouse colon cancer cells. Aldh7a1 This is the result of constructing the knockout (sgAldh7a1) cell line. Specifically, using qRT-PCR Aldh7a1 Confirmed expression. Gapdh Gene expression was used as an endogenous control. The primers used are as follows: Aldh7a1-Forward (5'-CCTCGTTAGTGTGGCTGTCACA-3': SEQ ID NO. 5), Aldh7a1-Reverse (5'-AAGGACAGCAGGTTCACACGCT-3': SEQ ID NO. 6), Gapdh-Forward (5'-CATCACTGCCACCCAGAAGACTG-3': SEQ ID NO. 7), Gapdh-Reverse (5'-ATGCCAGTGAGCTTCCCGTTCAG-3': SEQ ID NO. 8). Error bars represent the standard error. Figures 5c and 5d show wild (sgNT) or HCC78 human lung cancer cells. ALDH7A1 Knockout (sg ALDH7A1 -1, sg ALDH7A1 Figure 3) shows the results of the colony formation analysis after ASP1570 treatment. Specifically, Figure 5c is a representative well image, and Figure 5d is quantitative data on the number of colonies formed. The P-value was obtained through a two-tailed Student's t-test, and the error bars represent the standard error. Figures 5e and 5f show wild (sgNT) or CT-26 mouse lung cancer cells. Aldh7a1 Knockout (sg Aldh7a1 This is the result of the colony formation analysis after ASP1570 treatment in ). Specifically, Fig. 5e is a representative well image, and Fig. 5f is quantitative data on the number of colonies formed. The P-value was obtained through a two-tailed Student's t-test, and the error bars represent the standard error. Fig. 6 is ALDH7A1 This is a fluorescence image obtained after treating HCC95 human lung cancer cell lines that do not express ASP1570, and then treating cells attached to the plate (Plate) and cells that lost adhesion (Media) at the indicated time with Calcein AM, which labels live cells, and Ethidium Homodimer-1, which labels dead cells. Figure 7 shows the results of a comparison of relative cell survival by DGKZ knockout for HCC95 and HCC15 lung cancer cell lines in a 96-well study. In HCC95, an ALDH7A1-deficient cancer cell line, DGKZ knockout was observed to inhibit survival, whereas in HCC15, an ALDH7A1-expressing cancer cell line, DGKZ knockout did not inhibit survival. P-values ​​were obtained using a two-tailed Student's t-test, and error bars represent the standard error. Fig. 8 is ALDH7A1 This is the result of evaluating the metastasis-inhibiting efficacy of ASP1570 in the HCC95 squamous cell-deficient lung cancer cell line. (Left) Experimental flowchart. (Right) Figure showing the tumor burden between the ASP1570 0 mg / kg and 10 mg / kg groups. Normal bg (Normal background) represents the mean analysis value of mice that did not receive the cells, and the P-value was obtained through a two-tailed Student's t-test. Fig. 9a is ALDH7A1These are the results of the evaluation of anticancer efficacy by DGKZ inhibition in the HCC95 squamous cell-deficient lung cancer cell line. (Left) Experimental flowchart. (Right) Tumor growth graph between the sgNT and sgDGKZ groups. P-values ​​were obtained through two-way analysis of variance. Figure 9b shows the results of constructing sgNT or sgDGKZ cell lines of HCC95 human lung cancer cells. The expression of each protein was confirmed by Western blot using antibodies for DGKZ (Abcam, 105195, 1:1,000) and β-actin (Cell Signaling Technology, 4970, 1:1,000). Figure 10 shows the results of flow cytometry. (Left) The proportion of apoptotic cells was determined by flow cytometry using Annexin V and PI staining after treating HCC95 human lung cancer cells or SNU-1066 head and neck cancer cells with 0 μM or 3 μM of ASP1570. Error bars represent standard errors. (Right) The expression of proteins in the apoptotic pathway was determined by Western blot after treating HCC95 human lung cancer cells or SNU-1066 head and neck cancer cells with 0 μM or 3 μM of ASP1570. Caspase 8 (CASP8, Cell Signaling Technology, 4790), cleaved Caspase 8 (c-CASP8, Cell Signaling Technology, 9496), Caspase 3 (CASP3, Cell Signaling Technology, 9662), cleaved Caspase 3 (c-CASP3, Cell Signaling Technology, 9661), PARP (Cell Signaling Technology, 9661) 9542), cleaved PARP (c-PARP, Cell Signaling Technology, 9541), and β-ACTIN (Cell Signaling Technology, 4970) antibodies were used. Figure 11 shows TCGA squamous cell carcinoma. ALDH7A1 This is the result of the correlation analysis between promoter methylation and gene expression. The aggregated β-value on the x-axis is ALDH7A1 This is the average value of the promoter methylation scores. The correlation coefficient and P-value were obtained through the Spearman correlation test, and the red trend line represents the equation obtained through linear regression. Fig. 12 is ALDH7A1 This is the result confirming DNA promoter methylation. (Top) In bisulfite-treated DNA of human squamous cell lung cancer cell lines and (bottom) head and neck cancer cell lines ALDH7A1PCR results using promoter methylation-specific primers (M) or un-methylation-specific primers (U). ALDH7A1 In these inhibited cell lines (HCC95, H209, SNU-1066, FaDu), PCR products were detected only when methylation-specific primers were used, and ALDH7A1 In cell lines expressing (HCC2450, HCC15, SNU-899), PCR products were detected only when non-methylation-specific primers were used. Figure 13a is a schematic diagram of glycerolipid metabolism. ALDH7A1 is an enzyme that converts glyceraldehyde (GLAD) into glyceric acid (GA), and DGKZ is an enzyme that converts diacylglycerol (DAG) into phosphatidic acid (PA). DAG has been shown to affect various downstream cell membrane phospholipids. Fig. 13b is an empty vector or ALDH7A1 Overexpression of ( ALDH7A1 These are the DAG measurement results after treating HCC95 cells (-OE) with ASP1570. P-values ​​were obtained via two-way ANOVA, and error bars represent the standard deviation. Fig. 14a shows sgNT (WT) and sgDGKZ ( DGKZ KO) This is a volcano plot showing the differences in expression and significance between HCC95 cells. Each dot represents each gene, and the red dots DGKZ Inhibition (sg DGKZ , DGKZ It refers to genes whose expression increases upon KO, and the blue dots DGKZ It refers to genes whose expression is reduced by repression. Additionally, the green dots SPRR2 The genes included in the family were indicated. Fig. 14b is ALDH7A1After treating (top) human squamous cell lung cancer cell line HCC95 and (bottom) head and neck cancer cell line SNU-1066 that do not express ASP1570 SPRR2A , SPRR2D , SPRR2E This is the result of gene expression. The P-value was obtained using a two-tailed Student's t-test, and the error bars represent the standard error. Fig. 14c is ALDH7A1 After treating (top) human squamous cell lung cancer cell line HCC95 and (bottom) head and neck cancer cell line SNU-1066 that do not express DAG SPRR2A, SPRR2D, SPRR2E This is the result of gene expression. The P-value was obtained using a two-tailed Student's t-test, and the error bars represent the standard error. Fig. 14d is an empty vector or ALDH7A1 Overexpressing ( ALDH7A1 -OE) (Top) After treating human squamous cell lung cancer cell line HCC95 and (Bottom) head and neck cancer cell line SNU-1066 with ASP1570 SPRR2A, SPRR2D, SPRR2E This is the result of gene expression. The P-value was obtained using a two-tailed Student's t-test, and the error bars represent the standard error. Figure 14e shows the results of confirming the expression of genes within the SPRR2 gene family after delivering a lentivirus containing the sgNT or sgSPRR2D vector to the human squamous cell lung cancer cell line HCC95. Error bars represent the standard error. Fig. 14f is wild (WT) or SPRR2 Knockout ( SPRR2 KO) These are the results showing the relative survival rate after treating human squamous cell lung cancer cell line HCC95 with ASP1570. P values ​​were obtained using a two-tailed Student's t-test, and error bars represent the standard error. Figure 15a is a transmission electron microscope image taken after treating human squamous cell lung cancer cell line HCC95 with ASP1570. Figure 15b is a transmission electron microscope image taken after treating human head and neck cancer cell line SNU-1066 with ASP1570. Figure 15c shows the results of the Seahorse assay in which human squamous cell lung cancer cell line HCC95 was treated with ASP1570. Error bars represent the standard deviation. Figure 15d shows the results of the Seahorse assay in which human squamous cell head and neck cancer cell line SNU-1066 was treated with ASP1570. Error bars represent the standard deviation. Figure 15e shows the GP index calculated using Laurdan dye after treating human squamous cell lung cancer cell line HCC95 with ASP1570. P values ​​were obtained using a two-tailed Student's t-test, and error bars represent the standard deviation. The (left) side of Fig. 15f is the empty vector or ALDH7A1 Overexpression ( ALDH7A1 -OE) This is the GP indicator calculated via Laurdan dye after treating human squamous cell lung cancer cell line HCC95 with ASP1570. (Right) is wild (WT) or SPRR2 Knockout ( SPRR2 KO) This is the GP index calculated using Laurdan dye after treating human squamous cell lung cancer cell line HCC95 with ASP1570. P values ​​were obtained using a two-tailed Student's t-test, and error bars represent the standard deviation. The (left) side of Fig. 15g is the empty vector or ALDH7A1 Overexpression ( ALDH7A1-OE) This is a confocal fluorescence microscopy image of lipid raft (CT-B) stained after treating human squamous cell lung cancer cell line HCC95 with ASP1570. (Right) is a table quantifying the lipid raft fluorescence signal. P values ​​were obtained using a two-tailed Student's t-test, and error bars represent the standard error. Figure 15h (left) shows the results of confirming the amount of phospho-FAK and FAK proteins after treating HCC95 or (right) SNU-1066 cell lines with empty vector (Empty) or ALDH7A1 overexpression (ALDH7A1-OE) cell lines with ASP1570. Figure 15i (left) shows the results of determining the amount of phospho-FAK and FAK proteins after treating wild (WT) or SPRR2 knockout (SPRR2 KO) HCC95 or SNU-1066 cell lines with 0 μM or 1 μM ASP1570. Figure 15j (left) shows the results of determining the amount of phospho-FAK and FAK proteins after treating wild (WT) or ALDH7A1 knockout (ALDH7A1 KO) HCC15 or SNU-899 cell lines with 0 μM or 1 μM ASP1570. Figure 15k is a schematic diagram summarizing the synthetic lethal mechanism of ALDH7A1 and DGKZ. When DGKZ is inhibited with the drug ASP1570 in ALDH7A1-deficient squamous cell lung cancer cell lines, the amount of intracellular DAG increases. Consequently, the cornification-related gene SPRR2 Expression increases, and mitochondrial depolarization proceeds similarly to the differentiation process of normal keratinocytes. The hardness of the cell membrane increases, the structure of lipid rafts is inhibited, and FAK signaling decreases. In other words, it was revealed that the pattern of cell death in synthetic lethality is apoptosis. Specific details for implementing the invention

[0087] The present invention will be described in more detail below through examples. These examples are intended solely to explain the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited by these examples according to the gist of the invention.

[0089] [Preparation Example] Experimental Method

[0090] 1. Information on the cell line used and culture environment

[0091] All cells were cultured in a 37°C, 5% CO2 incubator. HEK293T (Human embryonic kidney 293 T) cells and lung cancer cell lines (HCC95, HCC15, HCC78, H3255, HCC2450) were purchased from ATCC (American Type Culture Collection), lung cancer cell line (H209) and head and neck cancer cell lines (SNU-1066, FaDu, SNU-899, SNU-1041) were purchased from the Korean Cell Line Bank, ABC-1 human lung cancer cells were purchased from JCRB (Japanese Cancer Research Resources Bank), and CT-26 mouse colorectal cancer cells, SNU-1066, FaDu (head and neck cancer), and CaSki (cervical cancer) cells were purchased from KCLB (Korean Cell Line Bank). HEK293T, ABC-1, CT-26, and FaDu cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, 11965092) supplemented with 10% fetal bovine serum (FBS) (Gibco, 16000-044) and 1% penicillin-streptomycin (Invitrogen, 15140122). The remaining cells were cultured in RPMI 1640 medium (Gibco, 11875093) supplemented with 5% FBS and 1% penicillin-streptomycin.

[0093] 2. ASP1570 drug

[0094] The drug ASP1570 is a drug that inhibits diacylglycerol kinase ζ (DGK-zeta) developed by Astellas Pharma (Patent: WO2021132422, CAS # 2660218-71-1). The purpose of this drug is to develop it as a treatment for cancers resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy, particularly cancers involving immune cell activation resistant to anti-PD-1 / anti-PD-L1 antibody therapy, and the compound / drug of the said structure was synthesized by Wuxi Apptec.

[0096] [Example 1] Differential expression of ALDH7A1 and DGKZ in squamous cell carcinoma

[0097] Comparing ALDH7A1 expression in tumor and normal tissues using transcriptome expression data registered in the TCGA (The Cancer Genome Atlas) project, it was confirmed that, unlike normal tissues, tumor tissues were divided into ALDH7A1 overexpression and underexpression groups (Fig. 2a). Furthermore, analysis of transcriptome data registered in the Cancer Cell Line Encyclopedia (CCLE, Broad Institute) project revealed a significant deficiency in the group where both ALDH7A1 and DGKZ expression were simultaneously reduced. This suggests that the deficiency of these two genes had an adverse effect on the survival of cancer cells (Fig. 2b).

[0099] [Example 2] Comparison of anticancer efficacy of ASP1570 inhibitor in ALDH7A1-deficient or expressing cancer cell lines

[0100] Confirmation of ALDH7A1-deficient and expressing cancer cell lines from CCLE data

[0101] Utilizing proteomics data (Depmap 22Q4 version) registered in the Cancer Cell Line Encyclopedia (CCLE, Broad Institute) project ALDH7A1We identified human lung cancer cell lines that express (HCC78, HCC15) or are deficient (ABC-1, HCC95, NCI-H3255), head and neck cancer cell lines (SNU-1066, FaDu) and cervical cancer cell lines (CaSki) that are deficient in ALDH7A1 (Fig. 3a). It was confirmed that the expression of ALDH7A1 was significantly suppressed in 8 of the 77 lung cancer cell lines, 7 of the 54 head and neck cancer cell lines, and 2 of the 12 cervical cancer cell lines.

[0103] Comparison of anticancer efficacy of ASP1570 in ALDH7A1-deficient and expressing cancer cell lines

[0104] ALDH7A1 We aimed to obtain drug response curves for ASP1570 in 96-well plates and evaluate the anticancer efficacy of ASP1570 using human lung cancer, head and neck cancer, and cervical cancer cell lines that were deficient or expressing ASP1570. One day prior to treatment with ASP1570, 3,000 cells were seeded into each well of a 96-well plate. The following day, the drug was administered at final concentrations of 0, 0.01, 0.03, 0.1, 0.32, 1, 3.17, 10.02, 31.65, and 100 μM, and the cells were cultured for 72 hours in a 37°C, 5% CO2 incubator. After 72 hours, the relative number of viable cells was compared using Cell-Titer Glo (Promega, G7573).

[0105] As a result, as shown in Figures 3b and 3c, it was confirmed that the anticancer effect of ASP1570 was superior in ALDH7A1-deficient cell lines (red) compared to ALDH7A1-expressing cell lines (black).

[0107] additionally ALDH7A1We aimed to obtain drug response curves for ASP1570 in 96-well plates using human head and neck cancer cell lines that were deficient or expressing ASP1570, and to evaluate the anticancer efficacy of ASP1570. One day prior to treatment with ASP1570, 1,000 cells were seeded into each well of a 96-well plate. The following day, the cells were treated with ASP1570 at final concentrations of 0, 0.01, 0.03, 0.1, 0.32, 1, 3.17, 10.02, 31.65, and 100 μM, and cultured for 72 hours in a 37°C, 5% CO2 incubator. After 72 hours, the relative number of viable cells was compared using Cell-Titer Glo (Promega, G7573).

[0108] As a result, as shown in Figure 3e, it was confirmed that the anticancer efficacy against ASP1570 was stronger in ALDH7A1-deficient cell lines compared to expression cell lines.

[0110] Anticancer efficacy by DGKZ inhibition in ALDH7A1-deficient cancer cell lines

[0111] 5 x 10^4 cells were seeded into 12 mm cover glasses (Marienfeld Superior, HSU-0111520) in a 24-well plate. After 24 hours, ASP1570 was treated at 0 μM or 0.3 μM. After 24 hours of drug treatment, the media was removed, and the cells were washed twice with PBS. Subsequently, the cells were fixed by treating with 4% paraformaldehyde (Biosesang, P2031) at room temperature for 15 minutes. Afterward, the cells were washed three times with PBS for 5 minutes each, and then treated with 0.1% Triton X-100 (Sigma-Aldrich, X100) at room temperature for 10 minutes to permeabilize them. Subsequently, the samples were washed three times with PBS for 5 minutes each, and then treated with a 1% bovine serum albumin (GenDEPOT, A0100) solution and blocked at room temperature for 1 hour. Afterward, Phalloidin-Alexa Fluor™ 488 (Thermofisher Scientific, A12379) diluted 1:200 was added to the blocking solution and incubated overnight at 4°C. Next, the samples were washed three times with PBS for 5 minutes each and treated with 1 µg / mL DAPI (4',6-diamidino-2-phenylinodle) (Thermofisher Scientific, 62248) for 10 minutes at room temperature. Afterward, the samples were washed twice with PBS for 5 minutes each and mounted on a microscope glass (Marienfeld Superior, 1000412) using Prolong Gold Antifade Reagent (Thermofisher Scientific, P36934). Images were acquired using a confocal fluorescence microscope LSM700 (Carl Zeiss).

[0112] As a result, as shown in Figure 3d, when the ALDH7A1-deficient HCC95 cell line was treated with the DGKZ inhibitor ASP1570, the cancer cells changed to a round shape and attached loosely and weakly to the culture plate, and detached over time. In addition, it was confirmed that the signal of fibrous actin (F-actin) stained with phalloidin was significantly reduced upon treatment with ASP1570.

[0114] [Example 3] Comparison of anticancer efficacy of ASP1570 inhibitor after ALDH7A1 overexpression in two ALDH7A1-deficient cancer cell lines

[0115] 1. HCC95 empty vector or ALDH7A1 Production of overexpression cell lines

[0116] One day before plasmid transfection, 7 x 10^5 HEK293T cells were seeded into a 60-mm plate. On the day of plasmid transfection, 6 μL of FuGENE® HD transfection reagent (Promega, E2311) was first thoroughly mixed with 74 μL of Opti-MEM™ I Reduced Serum Medium (Gibco, 31985088) and left at room temperature for 5 minutes. Subsequently, 1 µg of empty vector (Genecopedia, EX-NEG-Lv151) or ALDH7A1 overexpression vector (Genecopedia, EX-Z8294-Lv151), 0.25 µg of pMD2.G vector (Addgene, 12259), and 0.75 µg of psPAX2 vector (Addgene, 12260) were added to the solution containing FuGENE and incubated at room temperature for 15 minutes. The solution containing the plasmid and FuGENE was added to the medium of a 60-mm plate containing HEK293T and incubated in a 37°C, 5% CO2 incubator for 48 hours. The media was collected in a 15 mL conical tube and centrifuged at room temperature at 300 g for 5 minutes. After centrifugation, the supernatant containing the virus was collected and stored.

[0117] One day prior to delivery of the lentivirus containing a blank vector or an ALDH7A1 overexpression vector, 1 x 10^5 HCC95 cells were seeded into a 60-mm plate. Two hours prior to lentivirus delivery, the medium for the HCC95 and ABC-1 cells was replaced with 4 mL of medium containing 10 µg / mL of Polybrene (Sigma-Aldrich, H9268). Two hours later, 1 mL of lentivirus containing a blank vector or an ALDH7A1 overexpression vector was added to the HCC95 cell line. Forty-eight hours after lentivirus delivery, the medium was replaced with 800 µg / mL of G418 (Invivogen, ant-gn-1). The medium was replaced with new medium every 3 days, and after 2 weeks, the construction of the ABC-1 cell line with the empty vector or ALDH7A1 overexpressing HCC95 was completed.

[0119] 2. Comparison of anticancer efficacy of ASP1570 using colony formation assay in HCC95 covector or ALDH7A1 overexpressing cell lines

[0120] 5 x 10^4 cells were seeded into 12 mm cover glasses (Marienfeld Superior, HSU-0111520) in a 24-well plate. After 24 hours, ASP1570 was treated at 0 μM or 0.3 μM. After 24 hours of drug treatment, the medium was removed and the cells were washed twice with PBS. Subsequently, the cells were fixed by treating with 4% paraformaldehyde (Biosesang, P2031) at room temperature for 15 minutes. Afterward, the cells were washed three times with PBS for 5 minutes each, and then treated with 0.1% Triton X-100 (Sigma-Aldrich, X100) at room temperature for 10 minutes to make the cells permeable. Subsequently, the specimens were washed three times with PBS for 5 minutes each, treated with a 1% bovine serum albumin (GenDEPOT, A0100) solution, and blocked at room temperature for 1 hour. Then, Phalloidin-Alexa Fluor™ 488 (Thermofisher Scientific, A12379) diluted 1:200 was added to the blocking solution, and the specimens were incubated overnight at 4°C. Next, the specimens were washed three times with PBS for 5 minutes each, and treated with 1 µg / mL DAPI (4',6-diamidino-2-phenylinodle) (Thermofisher Scientific, 62248) for 10 minutes at room temperature. Afterward, the specimens were washed twice with PBS for 5 minutes each and mounted on a microscope glass (Marienfeld Superior, 1000412) using Prolong Gold Antifade Reagent (Thermofisher Scientific, P36934). Images were acquired using a confocal fluorescence microscope LSM700 (Carl Zeiss).

[0121] As a result, in ALDH7A1 overexpression (ALDH7A1-OE) cell lines, it was confirmed that the inhibitory effect on adhesion growth (anticancer effect) on culture plates treated with ASP1570 was weakened (Fig. 4b).

[0123] [Example 4] Comparison of Anticancer Effects of ASP1570 Inhibitor After ALDH7A1 Knockout (KO) in ALDH7A1 Wild (WT) Cancer Cell Lines

[0124] 1. HCC78 / CT-26 wild (WT) or ALDH7A1 Production of Knockout (KO) Cell Lines

[0125] 1-1. Preparation of Cas9-expressing cell lines

[0126] One day before plasmid transfection, 7 x 10^5 HEK293T cells were seeded into a 60-mm plate. On the day of plasmid transfection, 6 μL of FuGENE® HD transfection reagent (Promega, E2311) was first thoroughly mixed with 74 μL of Opti-MEM™ I Reduced Serum Medium (Gibco, 31985088) and left at room temperature for 5 minutes. Then, 1 μg of lentiCas9-Blast (Addgene, 52962), 0.25 μg of pMD2.G vector (Addgene, 12259), and 0.75 μg of psPAX2 vector (Addgene, 12260) were added to the solution containing FuGENE and left at room temperature for 15 minutes. The solution containing the plasmid and FuGENE was added to the medium of a 60-mm plate containing HEK293T and incubated in a 37°C, 5% CO2 incubator for 48 hours. The medium was collected in a 15 mL conical tube and centrifuged at room temperature at 300 g for 5 minutes. After centrifugation, the supernatant containing the virus was collected and stored.

[0127] One day prior to delivery of the lentivirus containing the lentiCas9-Blast plasmid, 1 x 10^5 HCC78 and CT-26 cells were seeded into a 60-mm plate. Two hours prior to delivery, the media for the HCC78 and CT-26 cells was replaced with 4 mL of medium containing 10 µg / mL Polybrene (Sigma-Aldrich, H9268). Two hours later, 1 mL of lentivirus containing either a blank vector or an ALDH7A1 overexpression vector was added to the HCC78 and CT-26 cell lines. Forty-eight hours after delivery, the medium was replaced with 20 µg / mL Blasticidin (Invivogen, ant-bl-1). The medium was replaced with fresh medium every three days, and the construction of the Cas9-expressing cell line was completed after one week.

[0129] 1-2. sgNT (single guide Non-Targeting), sgALDH7A1 (human being), sgAldh7a1 (Mouse) Plasmid Production

[0130] After selecting two human and one mouse sequences from the top sgRNA (single guide RNA) sequences searched for the gene name ALDH7A1 on CRISPick (https: / / portals.broadinstitute.org / gppx / crispick / public), respectively sgALDH7A1 -1 (5'-TCAATCAGCCCCAGTATGCG-3': Sequence No. 1) and sgALDH7A1 -3 (5'-ATTGAGCAGTGGAATCCCGT-3': Sequence No. 2), sgAldh7a1It was named (5'-GGGCTCCGCGAGGATAACGA-3': Sequence No. 3). Additionally, a non-targeting sgRNA (sgNT) sequence (5'-GCGAGGTATTCGGCTCCGCG-3': Sequence No. 4) that does not bind to any location in human and mouse genomic DNA sequences was also obtained. Each sgRNA was cloned into the lentiGuide-puro (Addgene, 52963) plasmid using the lentiCRISPR v2 cloning protocol (Sanjana, NE, Shalem, O. & Zhang, F. Nat. Methods, 2014.; Shalem, O. et al. Science, 2014.).

[0132] 1-3. sgRNA Virus Delivery and ALDH7A1 Knockout Cell Line Construction

[0133] One day before plasmid transfection, 7 x 10^5 HEK293T cells were seeded into a 60-mm plate. On the day of plasmid transfection, 6 μL of FuGENE® HD transfection reagent (Promega, E2311) was first thoroughly mixed with 74 μL of Opti-MEM™ I Reduced Serum Medium (Gibco, 31985088) and left at room temperature for 5 minutes. Then, 1 μg of sgRNA vector, 0.25 μg of pMD2.G vector (Addgene, 12259), and 0.75 μg of psPAX2 vector (Addgene, 12260) were added to the solution containing FuGENE and left at room temperature for 15 minutes. A solution containing the plasmid and FuGENE was added to the media of a 60-mm plate containing HEK293T and cultured in a 37°C, 5% CO2 incubator for 48 hours. The media was recovered into a 15 mL conical cube and centrifuged at room temperature at 300 g for 5 minutes. After centrifugation, the supernatant containing the virus was recovered and stored.

[0134] One day prior to delivery of the lentivirus containing the sgRNA vector, 1 x 10^5 Cas9-expressing HCC78 and CT-26 cells were seeded into 60-mm plates. Two hours prior to lentivirus delivery, the cell media was replaced with 4 mL of media containing 10 µg / mL PolyBrene (Sigma-Aldrich, H9268). Two hours later, 1 mL of lentivirus containing the sgRNA vector was added to the cell lines. Forty-eight hours after lentivirus delivery, the medium was replaced with media containing 10 µg / mL Puromycin (Invivogen, ant-pr-1). The medium was replaced with fresh media every three days, and after five days, wild or ALDH7A1 The production of knockout HCC78 and CT-26 cell lines was completed.

[0136] 2. HCC78 human lung cancer cell line wild or ALDH7A1 Comparison of Anticancer Efficacy of ASP1570 Using Colony Formation Analysis in Knockout Cell Lines

[0137] Wild (sgNT) or HCC78 human lung cancer cell line ALDH7A1 Knockout (sg ALDH7A1 -1, sg ALDH7A1-3) A colony formation assay was performed using the cell line. 1,000 cells were seeded into each well of a 6-well plate and treated with ASP1570 to a final concentration of either 0 μM or 1 μM. During the 2 weeks of cell culture in a 37°C, 5% CO2 incubator, the medium containing each concentration of ASP1570 was replaced every 3 days. 2 weeks after the initial treatment, the medium was removed, washed once with PBS, and then stained with a staining solution (distilled water containing 0.05% crystal violet and 6% glutaraldehyde) for 30 minutes at room temperature. Afterward, the staining solution was removed, the cells were washed under running tap water, and dried at room temperature. Clusters containing 50 or more cells were defined as colonies, and the number of colonies was counted visually under a microscope.

[0138] As shown in FIGS. 5c and 5d, ALDH7A1 It was confirmed that the inhibitory effect on colony formation by ASP1570 was stronger in knockout cells.

[0140] 3. CT-26 mouse colon cancer cells wild or Aldh7a1 Comparison of Anticancer Efficacy of ASP1570 Using Colony Formation Analysis in Knockout Cell Lines

[0141] Wild (sgNT) or CT-26 mouse colorectal cancer cell line Aldh7a1 Knockout (sg Aldh7a1A colony formation assay was performed using the cell line. 200 cells were seeded into each well of a 6-well plate, and the cells were treated with ASP1570 to achieve a final concentration of either 0 μM or 1 μM. During the 2 weeks of cell culture in a 37°C, 5% CO2 incubator, the medium containing each concentration of ASP1570 was replaced every 3 days. 2 weeks after the initial treatment, the medium was removed, washed once with PBS, and then stained with a staining solution (distilled water containing 0.05% crystal violet and 6% glutaraldehyde) for 30 minutes at room temperature. Afterward, the staining solution was removed, the cells were washed under running tap water, and dried at room temperature. Clusters containing 50 or more cells were defined as colonies, and the number of colonies was counted visually under a microscope.

[0142] As shown in FIGS. 5e and 5f, Aldh7a1 It was confirmed that the inhibitory effect on colony formation by ASP1570 was stronger in knockout cells.

[0144] [Example 5] Cell death due to loss of adhesion (anoikis) - ALDH7A1 When treating deficient cancer cell lines with ASP1570 inhibitor

[0145] Loss-adhesion apoptosis (anoikis) induced by treatment with the ASP1570 inhibitor was observed in ALDH7A1-deficient HCC95 human lung cancer cell lines in 96-well plates. One day prior to treatment with the ASP1570 drug, 5,000 cells were seeded into each well of a 96-well plate. The following day, the drug was administered so that the final concentration of ASP1570 was 0 μM or 3 μM. At 24 and 72 hours after drug treatment, the cell medium was replaced with media containing 2 μM Calcein AM (Thermofisher Scientific, 65-0853-78) and 2 μM Ethidium Homodimer-1 (Thermofisher Scientific, E1169), and the cells were incubated for 30 minutes in a 37°C, 5% CO2 incubator. Subsequently, the culture medium was transferred to a new 96-well plate, non-attached cells were transferred, and the existing plate containing attached cells was replaced with new medium. Fluorescence images of each well were acquired using an Olympus IX73 inverted microscope.

[0146] As shown in Figure 6, it was confirmed that cells that had lost adhesion after treatment with ASP1570 were alive in the media 24 hours after treatment with the drug, and that the cells died 72 hours after treatment with the drug, indicating that the process of loss-of-adhesion apoptotic cell death (apoptotic cell death that proceeds as adhesion is lost) occurred.

[0148] [Example 6] Apoptosis caused by loss-of-adhesion apoptosis (anoikis) - When DGKZ gene knockout cell line is treated with ASP1570 inhibitor

[0149] We wanted to determine whether the same phenomenon occurs when the diacylglycerol kinase ζ (DGK-zeta), which is inhibited by ASP1570, is deficient using genetic techniques.

[0151] 1. sg DGKZ Plasmid production

[0152] Gene names on CRISPick (https: / / portals.broadinstitute.org / gppx / crispick / public) DGKZ After selecting two of the top sgRNA (single guide RNA) sequences found by searching, each sg DGKZ -1 (5'-GAATAAGATGTTCTACGCCG-3': sequence number 9) and sg DGKZ -2 (5'-AGTTCCACGAGTCTCGAGGT-3': sequence number 10). Each sgRNA was cloned into the lentiGuide-puro (Addgene, 52963) plasmid using the lentiCRISPR v2 cloning protocol (Sanjana, NE, Shalem, O. & Zhang, F. Nat. Methods, 2014.; Shalem, O. et al. Science, 2014.).

[0154] 2. Confirmation of cancer cell survival after DGKZ knockout in ALDH7A1-deficient cell line HCC95 and expression cell line HCC15

[0155] Cas9-expressing HCC95 and HCC15 cell lines were prepared using the same process as in Example 4 (preparation of HCC78 and CT-26 Cas9-expressing cell lines).

[0156] One day prior to plasmid transfection, 7 x 10^5 HEK293T cells were seeded into a 60-mm plate. On the day of plasmid transfection, 6 μL of FuGENE® HD transfection reagent (Promega, E2311) was first thoroughly mixed with 74 μL of Opti-MEM™ I Reduced Serum Medium (Gibco, 31985088) and left at room temperature for 5 minutes. Subsequently, 1 μg of sgNT and sg were added to the solution containing FuGENE. DGKZ -1 or sg DGKZ-2 vector, 0.25 µg of pMD2.G vector (Addgene, 12259), and 0.75 µg of psPAX2 vector (Addgene, 12260) were added and incubated at room temperature for 15 minutes. The solution containing the plasmids and FuGENE was added to the medium of a 60-mm plate containing HEK293T and incubated in a 37°C, 5% CO2 incubator for 48 hours. The medium was collected into a 15 mL conical tube and centrifuged at room temperature at 300 g for 5 minutes. After centrifugation, the supernatant containing the virus was collected and stored.

[0157] One day prior to delivery of the lentivirus containing the sgRNA vector, 3 x 10^5 Cas9-expressing HCC95 and HCC15 cells were seeded into a 60-mm plate. Two hours prior to lentivirus delivery, the cell medium was replaced with 4 mL of medium containing 10 µg / mL of PolyBrene (Sigma-Aldrich, H9268). Two hours later, 1 mL of lentivirus containing the sgRNA vector was added to the cell lines. 48 hours after lentivirus delivery, the medium was replaced with medium containing 10 µg / mL of Puromycin (Invivogen, ant-pr-1). Three days after virus delivery, the number of surviving cells was counted using Trypan blue (Bio-rad, 1450021), and 1,000 cells were seeded into a 96-well plate and 1 x 10^5 cells into a 6-well plate. The relative number of viable cells in a 96-well plate was compared using Cell-Titer Glo (Promega, G7573) 96 hours after aliquoting.

[0158] As shown in Figure 7, in the ALDH7A1-deficient cancer cell line HCC95, the survival inhibition effect due to DGKZ knockout was observed, but in the ALDH7A1-expressing cancer cell line HCC15, survival inhibition by DGKZ knockout was not observed.

[0160] [Example 7] ASP1570 inhibitor in vivo Verification of anticancer effects in a mouse model

[0161] 1. ALDH7A1 Evaluation of metastasis inhibitory efficacy by ASP1570 in HCC95 squamous cell-deficient lung cancer cell line

[0162] ALDH7A1 We aimed to evaluate the metastasis-inhibiting efficacy of ASP1570 in a mouse model using HCC95, a human squamous cell lung cancer cell line deficient in metastasis. To induce a metastasis model, an HCC95 cell line expressing Incucyte® Cytolight Green (Satorious, 4705) was constructed. One day prior to delivery of the lentivirus containing the Incucyte® Cytolight Green expression vector, 1 x 10^5 HCC95 cells were seeded into a 60-mm plate. Two hours prior to delivery of the lentivirus, the HCC95 cell medium was replaced with 4 mL of medium containing 10 µg / mL of Polybrene (Sigma-Aldrich, H9268). Two hours later, the lentivirus containing the Incucyte® Cytolight Green expression vector was added. Twenty-four hours after lentivirus delivery, the medium was replaced with one containing 10 µg / mL of Puromycin (Invivogen, ant-puro-1). After three days, the construction of the Incucyte® Cytolight Green-expressing HCC95 cell line was completed.

[0163] Next, to establish a lung cancer metastasis model, 3 x 10^6 Incucyte® Cytolight Green-expressing HCC95 cells were injected into the tail veins of mice in 150 μL of PBS. Starting from the day the cell line was delivered to the tail vein, a 10 mg / kg dose of ASP1570 drug was administered to the mice once daily, dissolved in 200 μL of 0.5% methylcellulose. Nine weeks after cell line injection, the mice were euthanized, and the total lung tissue was collected. The collected lung tissue was pulverized at the cellular level using a Tumor dissociation kit (Miltenyl Biotec, 130-096-730), followed by flow cytometry analysis using an LSRFortessa (BD Biosciences) instrument. The ratio of cells expressing Incucyte® Cytolight Green to the total number of single cells was defined as the tumor burden.

[0164] As a result, as shown in Figure 8, it was confirmed that the tumor burden in the lung tissue of mice administered the DGKZ inhibitor ASP1570 was less than 0.2% compared to the control group.

[0166] 2. ALDH7A1 Evaluation of anticancer efficacy by DGKZ inhibition in HCC95 squamous cell lung cancer cell line

[0167] ALDH7A1We intended to evaluate the anticancer efficacy of DGKZ inhibition in a mouse model using HCC95, a human squamous cell lung cancer cell line deficient in squamous cells. In addition to the HCC95 cell line expressing Incucyte® Cytolight Green (Satorious, 4705) described above, cells expressing Cas9 were constructed. One day prior to delivery of the lentivirus containing the Cas9 expression vector (Addgene, 104995), 1 x 10^5 HCC95 cells were seeded into a 60-mm plate. Two hours prior to delivery of the lentivirus, the HCC95 cell medium was replaced with 4 mL of medium containing 10 µg / mL of Polybrene (Sigma-Aldrich, H9268). Two hours later, the lentivirus containing the Cas9 expression vector was added. Forty-eight hours after lentivirus delivery, the media was replaced with one containing 400 µg / mL of Hygromycin (Invivogen, ant-hygro-1). After 14 days, the Cas9-expressing HCC95 cell line was constructed. Subsequently, single-guide non-targeting (sgNT) or single-guide DGKZ (sg DGKZ Experiments were conducted to deliver ) to Cas9-expressing cells. The sgNT sequence used was the same as previously used, and the sgDGKZ sequence is as follows: 5'-GGTAGCCCCCTCCTCACCTG-3'. sgRNA cloning and lentivirus production were also carried out in the same manner as previously described.

[0168] Five days prior to mouse delivery, 1 x 10^7 cells of the Cas9-expressing HCC95 cell line were seeded into a 100-mm plate. Two hours prior to lentivirus delivery, the HCC95 cell medium was replaced with medium containing 10 µg / mL of Polybrene (Sigma-Aldrich, H9268). Two hours later, lentiviruses containing sgNT or sgDGKZ expression vectors were added. Twenty-four hours after lentivirus delivery, the medium was replaced with medium containing 10 µg / mL of Blasticidin (Invivogen, ant-blast-1). Subsequently, 3 x 10^6 cells were injected into the right flank of the mouse, diluted in 200 μL of 1:1 PBS:GelNest Matrix (Nest, 211262) solution. Tumor size was then measured using a caliper at 3 or 4-day intervals. Tumor size was calculated using the following formula: 0.5 x major axis length x minor axis length^2. Excess cells that were not delivered to mice after delivering lentiviruses containing sgNT or sgDGKZ expression vectors were seeded into 100-mm plates. After 2 days (6 days after lentivirus delivery), the cells were collected and used for Western blot experiments.

[0169] As a result, as shown in FIGS. 9a and 9b, DGKZ It was confirmed that inhibiting gene expression through CRISPR-Cas9, etc., exhibits anticancer effects, such as a reduction in tumor size.

[0171] [Example 8] Elucidation of the synthetic lethal mechanism of ALDH7A1 and DGKZ

[0172] 1. ALDH7A1 and DGKZ Synthetic lethality occurs through apoptosis (cell death).

[0173] Experiments were conducted to determine whether the apoptosis resulting from synthetic lethality was apoptotic cell death. For this purpose, 1 x 10^6 cells of human squamous cell lung cancer cell line HCC95 or head and neck cancer cell line SNU-1066, in which ALDH7A1 expression is inhibited, were seeded in 100-mm plates. Twenty-four hours after seeding, the cells were treated with ASP1570 at concentrations of 0 μM or 3 μM. Forty-eight hours after ASP1570 treatment, the cells were harvested, and the number of apoptotic cells was determined by flow cytometry using the BD Pharmingen FITC Annexin V Apoptosis Detection Kit I (BD Biosciences, 556547). In the same manner, the cells were treated with ASP1570, harvested, and Western blot analysis was performed to identify proteins expressed in the apoptotic pathway. The recovered cells were treated with RIPA buffer (Sigma-Aldrich, R0278) supplemented with Phosphatase Inhibitor (Gendepot, P3200-005) and Protease Inhibitor (Gendepot, P3100-005) and incubated at 4°C for 15 minutes. The lysed cells were centrifuged at 21,000 g for 15 minutes at 4°C to separate the supernatant. 10 µg of protein was electrophoresed onto a 4-15% Mini-PROTEAN TGX Precase Protein Gel (Bio-Rad, 4561084) and then transferred to an Immun-Blot PVDF Membrane (Bio-Rad, 1620174). The PVDF membrane was blocked by shaking at low speed for 1 hour at room temperature after treatment with Smart-Block 5 min-Fast Blocking Buffer (Biomax, BWB-0500), then treated with the primary antibody and incubated overnight at 4°C. Afterward, it was washed with PBS-T three times for 10 minutes each, treated with the secondary antibody, and incubated by shaking at low speed for 1 hour at room temperature.Afterward, the sample was washed with PBS-T three times for 10 minutes each, and then the protein was detected using Pierce ECL Western Blotting Substrate (Thermo Scientific, 32109).

[0174] As a result, as shown in Figure 10, it was confirmed that the expression of proteins expressed in the apoptosis pathway increased in cancer cells treated with the DGKZ inhibitor ASP1570.

[0176] 2. ALDH7A1 Regulation of expression occurs through DNA methylation

[0177] ALDH7A1 We wanted to determine whether the mechanism of inhibition of expression was due to methylation of the DNA promoter region.

[0178] To this end, oncogene expression and methylation data from patients with squamous cell lung cancer (LUSC), head and neck cancer (HNSC), cervical cancer (CESC), and bladder cancer (BLCA) from the TCGA (The Cancer Genome Atlas) were collected using the SMART app (bioinfo-zs.com / smartapp). The following ALDH7A1 Correlation analysis was performed between the methylation score of the gene's promoter region and gene expression.

[0179] As a result, as shown in Figure 11, by confirming an inverse correlation (increased methylation, decreased gene expression) in patient tumor samples ALDH7A1 It was confirmed that the expression of is regulated through DNA methylation.

[0181] Subsequently, in human squamous cell lung cancer cell lines and head and neck cancer cell lines ALDH7A1We aimed to investigate differences in DNA methylation according to expression. To this end, 5 x 10^5 cells were harvested, and genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, 513060). Subsequently, bisulfite conversion was performed on 1 µg of DNA using the EZ DNA Methylation-Lightning Kit (Zymo Research, D5030). Methylation-specific or non-methylation-specific primers were designed using Methprimer (methprimer.com), and PCR (Polymerase Chain Reaction) was performed using nTaq-HOT (Enzynomics, P750). The PCR conditions are as follows. Initial denaturation at 95 ℃, 10 min, (Denaturation at 95 ℃, 30 sec, Annealing at 60 ℃, 30 sec, Elongation at 72 ℃, 30 sec) 35 cycles, final elongation at 72 ℃, 5 min. The PCR products were electrophoresed on a 2% agarose gel. The methylation-specific primers used were 5'-TGGGCGTTTGTAATTTTAGTTACGT-3' and 5'-ACTACTCTCGAACTCCTAACCTCGTA-3', and the non-methylation-specific primers were 5'-GGTGGGTGTTTGTAATTTTAGTTATGT-3' and 5'-ACTACTCTCAAACTCCTAACCTCATA-3'.

[0182] As a result, as shown in Fig. 12, ALDH7A1 In this inhibited cell line, PCR products were generated only when methylation-specific primers were used, and ALDH7A1 It was confirmed that PCR products were generated in cell lines expressing [it] only when non-methylation-specific primers were used. Through this, ALDH7A1 It was confirmed that the expression of is due to methylation of the DNA promoter region.

[0184] 3. ALDH7A1 Confirmation of increased DAG upon inhibition of DGKZ by ASP1570 treatment in deficient squamous cell carcinoma cell lines

[0185] ALDH7A1 and DGKZ are located in close proximity to each other in glycerolipid metabolism (Fig. 13a). Therefore, if both genes are lost simultaneously, a more rapid accumulation of diacylglycerol (DAG) within the cell is expected compared to the loss of a single gene. To confirm this, human squamous cell lung cancer cell lines HCC95, either empty (empty vector) or overexpressing ALDH7A1 (ALDH7A1-OE), were treated with ASP1570 at concentrations of 0, 0.3, and 1 μM for 24 hours, after which the cells were harvested. The amount of intracellular DAG in the harvested cells was measured using a Diacylglycerol Assay Kit (Abcam, ab242293).

[0186] As a result, as shown in Fig. 13b, through this ALDH7A1 and DGKZ It was observed that DAG increased rapidly in environments where was simultaneously deficient, and ALDH7A1 If you overexpress it DGKZ It was confirmed that the increase in DAG due to inhibition was reduced.

[0188] 4. ALDH7A1 Increase in SPRR2 family gene expression upon DGKZ inhibition in deficient squamous cell carcinoma cell lines

[0189] ALDH7A1 RNA sequencing was performed to investigate transcriptomic changes caused by increased DAG upon DGKZ inhibition in squamous cell carcinoma cell lines. To this end, ALDH7A1As described above, a cell line expressing Cas9 was constructed from the human squamous cell lung cancer cell line HCC95, which does not express sgNT. Subsequently, lentiviruses containing vectors expressing sgNT or sgDGKZ were delivered to the cell lines, followed by treatment with 10 µg / mL puromycin (Invivogen, ant-pr-1) for 5 days. RNA was then extracted from the cells using the RNeasy Mini Kit (Qiagen, 74104). The mRNA-enriched sequencing library was prepared using the TruSeq Stranded mRNA Sample Prep Kit (Illumina, 20020594), and 150-bp paired-end sequencing was performed using a NovaSeq 6000 (Illumina). Raw reads were aligned to the reference human genome (GRCh38) using STAR (version 2.5.4), and gene-level count data was generated. To obtain genes showing differences in expression between sgNT and sgDGKZ, the R programming package DESeq2 (version 1.38.3) was used, and genes with FDR (False Discovery Rate) < 0.1 and log2fold change > 1 were defined as significant genes.

[0190] As a result, as shown in Fig. 14a, DGKZ A significant number of when suppressed SPRR2 We observed that the expression of family genes increased simultaneously.

[0192] In order to re-verify this ALDH7A1 After inhibiting DGKZ by treating human squamous cell lung cancer cell line HCC95 and head and neck cancer cell line SNU-1066 with suppressed expression with the drug ASP1570, SPRR2A , SPRR2D , SPRR2EThe expression of was confirmed via qRT-PCR. 2 x 10^5 cells were seeded into 6-well plates one day prior to ASP1570 drug treatment and treated with ASP1570 at concentrations of 0 or 1 μM. 24 hours after drug treatment, RNA was extracted from the cells using the RNeasy Mini Kit (Qiagen, 74104). Subsequently, 1 μg of RNA was reverse transcribed into cDNA using the PrimeScript RT Master Mix (Takara, RR036A). Then, qRT-PCR was performed using the TOPreal qPCR 2X PreMIX (SYBR Green with high ROX) (Enzynomics, RT501M) on a StepOnePlus Real-Time PCR instrument (Applied Biosystems). The β-tubulin gene (TUBB) was used as a control gene, and the SPRR2A The primer sequences are 5'-CTGGACCGCATCTCTGTGTACT-3' and 5'-GCCAAAAGGACCTGAGCGAACA-3'. SPRR2D The primers are 5'-AGTCAAAGTATCCAC CGAAGAGC-3' and 5'-AGGGATCATCATGGGCAGATTACT G-3', and SPRR2E The primers were 5'-GAGCTAAGAAAAGGAAGTCCTCA-3' and 5'-TTATTCAGGGAGTGAAAGATAAAT-3'. The qRT-PCR conditions were performed as follows: Initial denaturation at 95 ℃ for 10 minutes, (Denaturation 95 ℃ for 10 seconds, Annealing 60 ℃ for 15 seconds, Elongation 72 ℃ for 30 seconds) for 40 cycles, and relative gene expression was calculated using the ΔΔCt method.

[0193] As a result, as shown in Fig. 14b, ALDH7A1 When DGKZ was inhibited by ASP1570 in two cell lines, HCC95 and SNU-1066, that do not express SPRR2A , SPRR2D and SPRR2E We re-verified that the expression increased in all cases.

[0195] Subsequently, increased DAG in a synthetic lethal environment SPRR2 Experiments were conducted to determine whether it was the cause of the increased expression of family genes. To this end, ALDH7A1 By treating human squamous cell lung cancer cell line HCC95 and head and neck cancer cell line SNU-1066 with suppressed expression to DAG SPRR2A, SPRR2D, SPRR2E The expression of was confirmed via qRT-PCR. 2 x 10^5 cells were seeded into 6-well plates one day prior to DAG treatment and treated with DAG (MedChemExpress, HY-131897) at concentrations of 0 or 25 μM. 24 hours after DAG treatment, RNA was extracted from the cells using the RNeasy Mini Kit (Qiagen, 74104). Subsequently, 1 μg of RNA was reverse transcribed into cDNA using PrimeScript RT Master Mix (Takara, RR036A). Then, qRT-PCR was performed using the StepOnePlus Real-Time PCR instrument (Applied Biosystems) with TOPreal qPCR 2X PreMIX (SYBR Green with high ROX) (Enzynomics, RT501M). The β-tubulin gene (TUBB) was used as a control gene, and the SPRR2A The primer sequences are 5'-CTGGACCGCATCTCTGTGTACT-3' and 5'-GCCAAAAGGACCTGAGCGAACA-3', and SPRR2D The primers are 5'-AGTCAAAGTATCCAC CGAAGAGC-3' and 5'-AGGGATCATCATGGGCAGATTACT G-3', and SPRR2EThe primers were 5'-GAGCTAAGAAAAGGAAGTCCTCA-3' and 5'-TTATTCAGGGAGTGAAAGATAAAT-3'. The qRT-PCR conditions were performed as follows: Initial denaturation at 95 ℃ for 10 minutes, (Denaturation 95 ℃ for 10 seconds, Annealing 60 ℃ for 15 seconds, Elongation 72 ℃ for 30 seconds) for 40 cycles, and relative gene expression was calculated using the ΔΔCt method.

[0196] As a result, as shown in FIG. 14c, ALDH7A1 When DAG was treated extracellularly in two cell lines, HCC95 and SNU-1066, that do not express SPRR2A , SPRR2D and SPRR2E It was confirmed that the expression of all of them increased.

[0198] also, ALDH7A1 When overexpressed, the increase caused by DGKZ inhibition SPRR2 Experiments were conducted to determine whether the expression of family genes is suppressed. To this end, an empty vector or ALDH7A1 Overexpression ( ALDH7A1 By treating human squamous cell lung cancer cell line HCC95 and head and neck cancer cell line SNU-1066 expressing -OE with ASP1570 SPRR2A, SPRR2D, SPRR2EThe expression of was confirmed via qRT-PCR. 2 x 10^5 cells were seeded into 6-well plates one day prior to ASP1570 treatment and treated with ASP1570 at concentrations of 1 or 25 μM. 24 hours after ASP1570 treatment, RNA was extracted from the cells using the RNeasy Mini Kit (Qiagen, 74104). Subsequently, 1 μg of RNA was reverse transcribed into cDNA using PrimeScript RT Master Mix (Takara, RR036A). Then, qRT-PCR was performed using the TOPreal qPCR 2X PreMIX (SYBR Green with high ROX) (Enzynomics, RT501M) on a StepOnePlus Real-Time PCR instrument (Applied Biosystems). The β-tubulin gene (TUBB) was used as the control gene, and the SPRR2A The primer sequences are 5'-CTGGACCGCATCTCTGTGTACT-3' and 5'-GCCAAAAGGACCTGAGCGAACA-3', and SPRR2D The primers are 5'-AGTCAAAGTATCCAC CGAAGAGC-3' and 5'-AGGGATCATCATGGGCAGATTACT G-3', and SPRR2E The primers were 5'-GAGCTAAGAAAAGGAAGTCCTCA-3' and 5'-TTATTCAGGGAGTGAAAGATAAAT-3'. The qRT-PCR conditions were performed as follows: Initial denaturation at 95 ℃ for 10 minutes, (Denaturation 95 ℃ for 10 seconds, Annealing 60 ℃ for 15 seconds, Elongation 72 ℃ for 30 seconds) for 40 cycles, and relative gene expression was calculated using the ΔΔCt method.

[0199] As a result, as shown in FIG. 14d, ALDH7A1 When overexpressed, increased by ASP1570 treatment in two cell lines, HCC95 and SNU-1066 SPRR2A, SPRR2Dand SPRR2E It was confirmed that all expression was suppressed.

[0201] Next, SPRR2 Experiments were conducted to demonstrate that gene expression of a gene family is essential for synthetic lethality. To this end, an SPRR2D knockout HCC95 cell line was constructed. The sgSPRR2D vector was cloned using the same method as described above, and the sgRNA sequence used is as follows: 5'-GCTGTGGACACTTTGGTGAT-3'. At this time SPRR2A , SPRR2D and SPRR2E It was confirmed that the expression of all genes was suppressed. One day prior to treatment with the ASP1570 drug, 1,000 cells were seeded into each well of a 96-well plate. The following day, the drugs were administered at final concentrations of ASP1570 of 0, 0.01, 0.03, 0.1, 0.32, 1, 3.17, 10.02, 31.65, and 100 μM, and the cells were cultured for 72 hours in a 37°C, 5% CO2 incubator. After 72 hours, the relative number of viable cells was compared using Cell-Titer Glo (Promega, G7573).

[0202] As a result, as shown in FIGS. 14e and 14f, through this SPRR2 It was confirmed that resistance to ASP1570 developed in knockout cell lines compared to wild cell lines. Through this, SPRR2 It was confirmed that gene expression of the gene family is essential for synthetic lethality.

[0204] 5. Reduced mitochondrial respiration upon ASP1570 treatment in ALDH7A1-deficient squamous cell carcinoma cell lines

[0205] Furthermore, the SPRR2 (Small Proline-Rich Proteins 2) gene is known to contribute to differentiation in normal keratinocytes. During the normal differentiation process, keratinocytes gradually transform into cells that constitute the outer layer of the skin through cornification, and the expression of SPRR2 family genes increases during this process. Histologically, keratinocytes are a type of squamous epithelial cell, ALDH7A1 When DGKZ is inhibited in this suppressed squamous cell carcinoma SPRR2 The increased expression of genes led to the hypothesis that the mechanism of synthetic lethality could induce apoptosis through a mechanism similar to the differentiation process of normal keratinocytes. Accordingly, the inventors conducted experiments to verify this hypothesis.

[0207] It is known that normal mitochondrial function is inhibited within cells during the differentiation process of normal keratinocytes. Therefore ALDH7A1Human squamous cell lung cancer cell line HCC95 and head and neck cancer cell line SNU-1066, in which expression was suppressed, were treated with the drug ASP1570 to inhibit DGKZ, and then mitochondrial morphology was observed via electron microscopy. One day prior to treatment with ASP1570, 1 x 10^6 cells were seeded into 100-mm plates and treated with ASP1570 at concentrations of 0 or 1 μM. 24 hours after drug treatment, the cells were harvested and subjected to primary fixation for 12 hours in a mixture of 2% glutaraldehyde (Fisher Chemical) and 2% paraformaldehyde (Sigma-Aldrich) prepared in 0.1 M phosphate buffer (pH 7.4) (Sigma-Aldrich), followed by washing with 0.1 M phosphate buffer. Subsequently, post-fixation was performed for 2 hours using a 1% OsO4 solution (Polysciences) prepared in 0.1 M phosphate buffer. Dehydration was carried out using a gradual dehydration method with ethanol-based solutions of varying concentrations (50, 60, 70, 80, 90, 95, 100, 100%) for 10 minutes at each stage, followed by infiltration treatment in propylene oxide (Thermo-Fisher Scientific) for 10 minutes. Specimens were embedded using the Poly / Bed 812 kit and polymerized in an electron microscope oven (TD-700, Dosaka) at 70°C for 12 hours.

[0208] Sections of the resin block were prepared using an ultrathin sectioner (UC7; Leica) equipped with a diamond knife. First, a 200 nm thick semi-thin section was prepared, stained with 1% Toluidine O (Sigma-Aldrich), and an observation area was selected using an optical microscope. Subsequently, an 80 nm thick thin section was prepared from the selected area, placed on a copper grid, and double stained with 5% uranyl acetate (EMS) for 20 minutes and 3% lead citrate (Leica) for 7 minutes. The stained sections were observed and photographed using a transmission electron microscope (HT7800; Hitachi) operated at an acceleration voltage of 100 kV, equipped with an RC camera.

[0209] As a result, as shown in Figures 15a and 15b, it was possible to confirm that normal mitochondria were lost in HCC95 or SNU-1066 cell lines treated with ASP1570.

[0211] Next, we investigated whether oxidation phosphorylation was inhibited due to mitochondrial loss. To do this, ALDH7A1Oxygen consumption rate (OCR) was measured by performing the Seahorse Assay after inhibiting DGKZ in human squamous cell lung cancer cell line HCC95 and head and neck cancer cell line SNU-1066 with suppressed DGKZ expression by treating them with the drug ASP1570. One day prior to ASP1570 treatment, 1 x 10^3 cells were seeded into wells of a Seahorse XFe96 Cell Culture Microplate (Agilent, 103794) onto a 100-mm plate, and ASP1570 was administered at concentrations of 0 or 3 μM. Six hours after drug treatment, the cells were washed three times with Seahorse XF RPMI medium, pH 7.4 (Agilent, 103576). Subsequently, the experiment was conducted using a Seahorse XFe96 analyzer (Agilent). The drugs used for the seahorse assay were the XF Cell Mito Stress Test Kit (Agilent, 103015). Specifically, OCR was measured by sequentially administering 1 μM Oligomycin 15 minutes after the start of the assay, 0.25 μM FCCP for HCC95 and 1 μM FCCP for SNU-1066 35 minutes after the assay, and 0.5 μM Rotenone / Antimycin A 55 minutes after the assay.

[0212] As a result, as shown in Figures 15c and 15d, experimental results confirmed that overall oxidative phosphorylation was inhibited in both HCC95 and SNU-1066 cell lines treated with ASP1570.

[0214] 6. ALDH7A1 Increase in cell membrane hardness upon ASP1570 treatment in deficient squamous cell carcinoma cell lines

[0215] Keratinocytes gradually transform into cells constituting the outer layer of the skin through cornification during the normal differentiation process, and during this process, the expression of SPRR2 family genes increases. Cornification refers to the phenomenon in which skin tissue forms keratin, and during this process, proteins such as SPRR2, LORICRIN, and TGM3 aggregate on the cell membrane of keratinocytes. Additionally, lipids constituting the cell membrane, such as phospholipids, ceramides, and cholesterol, aggregate. As a result, it has been reported that the hardness of the cell membrane increases. Therefore, the inventors conducted an experiment to confirm whether the hardness of the cell membrane increases when synthetic lethality occurs. To this end ALDH7A1 Human squamous cell lung cancer cell line HCC95, which does not express [the virus], was seeded into each well of a 96-well plate at a density of 1 x 10^3 cells and treated with ASP1570 at concentrations of 0 μM, 0.3 μM, and 1 μM. After 24 hours of ASP1570 treatment, the cells were washed twice with PBS. Subsequently, the medium was changed to PBS containing 5 μM of Laurdan dye (MedChemExpress, HY-D0080), and the cells were incubated for 1 hour at 37°C in a 5% CO2 environment. After washing twice with PBS, the fluorescence intensity was measured using a Varioskan LUX multimode plate reader (ThermoFisher Scientific). An excitation wavelength of 340 nm was used, and emissions were measured at wavelengths of 440 nm and 490 nm. The generalized polarization (GP) index representing hardness was calculated using the following formula: GP = (I440-I490) / (I440+I490), where I440 represents the absorbance at 440 nm and I490 represents the absorbance at 490 nm.

[0216] As a result, as shown in Figure 15e, the GP value of HCC95 cells increased significantly upon treatment with ASP1570, indicating an increase in cell membrane hardness. Additionally, using the same experimental method ALDH7A1 HCC95 overexpressing (HCC95 ALDH7A1 -OE) or HCC95 inhibited by SPRR2 ( SPRR2 It was confirmed that in the KO) cell line, the hardness of the cell membrane did not increase even when treated with ASP1570 (Fig. 15f).

[0218] 7. ALDH7A1 Reduction in lipid raft structure upon ASP1570 inhibition in deficient squamous cell carcinoma cell lines

[0219] The inventors hypothesized that the components of the cell membrane essential for cell survival were affected due to an increase in cell membrane hardness. Among these, lipid rafts are structures in which specific signaling molecules are aggregated on the cell membrane, playing a major role in maintaining survival by transmitting signals important for cell survival from the outside to the inside of the cell. The inventors hypothesized that the structure of lipid rafts was inhibited through a mechanism of synthetic lethality. To verify this, human squamous cell lung cancer cell line HCC95 was seeded at a density of 5 x 10^4 cells in a 12 mm cover glass (Marienfeld Superior, HSU-0111520) in a 24-well plate. 24 hours after seeding, ASP1570 was treated at 0 μM or 0.3 μM. 24 hours after drug treatment, the media was removed, and the cells were washed twice with PBS. Then, lipid rafts on the cell membrane were fluorescently labeled using the Vybrant Alexa Fluor 555 Lipid Raft Labeling Kit (Invitrogen, V34404). Subsequently, cells were fixed by treating with 4% Paraformaldehyde (Biosesang, P2031) at room temperature for 15 minutes. Afterward, the cells were washed three times with PBS for 5 minutes each, followed by treatment with 0.1% Triton X-100 (Sigma-Aldrich, X100) at room temperature for 10 minutes to permeabilize them. Afterward, the cells were washed three times with PBS for 5 minutes each, and treated with 1 µg / mL DAPI (4',6-diamidino-2-phenylinodle) (Thermofisher Scientific, 62248) at room temperature for 10 minutes. Afterward, it was washed twice with PBS for 5 minutes each time, and then mounted on a microscope glass (Marienfeld Superior, 1000412) using Prolong Gold Antifade Reagent (Thermofisher Scientific, P36934).Images were acquired using a confocal fluorescence microscope LSM700 (Carl Zeiss). Lipid raft fluorescence was quantified using the ImageJ program.

[0220] As a result, as shown in Fig. 15g, ALDH7A1 In contrast to the reduction of lipid rafts by the drug ASP1570 in HCC95 cell lines that do not express, ALDH7A1 In the case of cells overexpressing [it], the corresponding decrease was not observed.

[0222] 7. ALDH7A1 Reduced FAK signaling upon ASP1570 inhibition in deficient squamous cell carcinoma cell lines

[0223] The inventors confirmed that the structure of lipid rafts is inhibited by the mechanism of synthetic lethality, and hypothesized that integrin beta 1, which is essential for cell survival among the lipid raft structures, and the downstream Focal Adhesion Kinase signaling pathway are inhibited, leading to apoptosis. To verify this, an empty vector, ALDH7A1 Overexpression ( ALDH7A1 -OE), wild (WT) and SPRR2 Knockout ( SPRR2 KO) Protein expression of the FAK signaling pathway was confirmed by Western blotting after treating squamous lung cancer cell line HCC95 or head and neck cancer cell line SNU-1066 with ASP1570. For this purpose, 5 x 10^5 cells were seeded in 60-mm plates and treated with ASP1570. Western blotting was performed 48 hours after drug treatment in the same manner as described above. FAK antibody (Cell Signaling Technologies, 3285) and phospho-FAK (Y397) antibody (Abcam, ab81298) were used.

[0224] As a result, as shown in Fig. 15h, a decrease in FAK signaling (decrease in phospho-FAK) induced by ASP1570 was observed in ALDH7A1-non-expressing (Empty) or wild (WT) cell lines, and this phenomenon ALDH7A1 Overexpression of ( ALDH7A1 -OE) or SPRR2 Knockout ( SPRR2 was rescued by KO.

[0226] Conversely, we aimed to determine whether the FAK signaling pathway is reduced by drug treatment with ASP1570 when ALDH7A1 is knocked out in cell lines expressing ALDH7A1. When Western blot was performed using the same experimental method, the FAK signaling pathway was not inhibited even with ASP1570 treatment in WT human squamous cell lung cancer cell line HCC15 or head and neck cancer cell line SNU-899, however ALDH7A1 In cell lines knocked out, it was confirmed that FAK signaling was inhibited by treatment with the drug ASP1570 (Figs. 15i and 15j).

[0228] Foregoing, specific parts of the present invention have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.

Claims

Claim 1 A pharmaceutical composition for the prevention or treatment of cancer comprising a diacylglycerol kinase ζ (DGK-zeta) inhibitor as an active ingredient. Claim 2 A pharmaceutical composition according to claim 1, wherein the cancer is an ALDH7A1 negative cancer. Claim 3 A pharmaceutical composition according to paragraph 2, wherein the cancer is an immune checkpoint inhibitor (ICI) resistant cancer. Claim 4 A pharmaceutical composition according to claim 3, wherein the immune checkpoint inhibitor is one or more selected from the group consisting of PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, and TIM-3. Claim 5 A pharmaceutical composition according to paragraph 2, wherein the cancer is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, renal cell carcinoma, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma, or lung cancer. Claim 6 A pharmaceutical composition according to claim 5, wherein the cancer is squamous cell cancer. Claim 7 A pharmaceutical composition according to claim 6, wherein the diacylglycerol kinase ζ inhibitor is one or more selected from the group consisting of a small molecule inhibiting diacylglycerol kinase ζ, a diacylglycerol kinase ζ antagonist, an antibody or antigen-binding fragment specifically binding to diacylglycerol kinase ζ, and an antisense nucleotide binding complementarily to the transcript sequence of diacylglycerol kinase ζ. Claim 8 A pharmaceutical composition according to claim 7, wherein the small molecule inhibiting the diacylglycerol kinase ζ is one or more selected from the group consisting of ASP1570, Veludacigib (BAY 29665501), and DGKζ-IN-3 (CAS No. : 2732901-70-9). Claim 9 A pharmaceutical composition according to claim 7, wherein the antisense nucleotide that binds complementarily to the transcript base sequence of the diacylglycerol kinase ζ is one or more selected from the group consisting of short interfering RNA (siRNA), microRNA (mircoRNA; miRNA), short hairpin RNA and ribozyme, dsNRA, aptamer, PNA (peptide nucleic acid), ZFN, TALEN and CRISPR (cluster regularly interspaced short palindromic repeats) related nucleic acid, single guide RNA (sgRNA), CRISPR-RNA (crRNA), and trans-activated crRNA (tracrRNA). Claim 10 A method for screening cancer patients in which a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective for cancer prevention or treatment. Claim 11 In paragraph 10, a method for screening cancer patients in which the above cancer is an ALDH7A1 negative cancer. Claim 12 A composition for diagnosing cancer patients effective with a diacylglycerol kinase ζ (DGK-zeta) inhibitor, comprising: a preparation for measuring the expression level of a fragment of ALDH7A1 protein or a gene encoding it; or a preparation for measuring whether the gene encoding said ALDH7A1 protein is methylated. Claim 13 In Clause 12, the above-mentioned cancer is an ALDH7A1 negative cancer, a diagnostic composition. Claim 14 In claim 13, the preparation for measuring the expression level of the protein comprises one or more selected from the group consisting of antibodies, oligopeptides, ligands, PNA (peptide nucleic acid), and aptamers that specifically bind to the protein, for diagnostic composition. Claim 15 In claim 13, the preparation for measuring the expression level of the said gene comprises one or more selected from the group consisting of primers, probes, and antisense nucleotides that specifically bind to the said gene, a diagnostic composition. Claim 16 A diagnostic composition according to claim 12, wherein the methylation status of the gene encoding the ALDH7A1 protein is measured by determining the methylation status of the promoter region of the gene encoding the ALDH7A1 protein. Claim 17 In paragraph 13, the above composition is a diagnostic composition intended for application to a biological sample isolated from a target individual. Claim 18 In paragraph 16, the biological samples are whole blood, leukocytes, peripheral blood mononuclear cells, buffy coat, plasma, serum, sputum, tears, mucus, nasal washes, nasal aspirate, breath, urine, semen, saliva, peritoneal washings, ascites, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspirate, synovial fluid, joint aspirate A diagnostic composition comprising one or more selected from the group consisting of aspirate, organ secretions, cell, cell extract, and cerebrospinal fluid. Claim 19 A diagnostic kit comprising a diagnostic composition according to any one of claims 12 to 18. Claim 20 In paragraph 19, the above kit is a diagnostic kit that is an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or an MRM (Multiple reaction monitoring) kit. Claim 21 A method for providing information for diagnosing cancer patients in which a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective, comprising: a step of measuring, in a biological sample isolated from a target individual, a fragment of ALDH7A1 protein; the expression level of the gene encoding it; or whether the gene encoding the ALDH7A1 protein is methylated; and a step of determining that a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective if the ALDH7A1 protein fragment measured in the biological sample; or the expression level of the gene encoding it, is lower than that of a control group. Claim 22 (a) a step of measuring, in a biological sample isolated from a target individual, a fragment of ALDH7A1 protein; the expression level of a gene encoding it; or whether the gene encoding said ALDH7A1 protein is methylated; a measuring unit for measuring the fragment of ALDH7A1 protein; or the expression level of the gene encoding it measured in said biological sample; and (b) a detection unit for outputting whether a diacylglycerol kinase ζ (DGK-zeta) inhibitor is effective in a cancer patient from the expression level of the gene or the protein encoded by said gene measured by said measuring unit; a diagnostic device for a cancer patient comprising: Claim 23 A method for determining whether the expression of ALDH7A1 protein is inhibited, comprising the step of measuring whether the gene encoding ALDH7A1 protein is methylated. Claim 24 In paragraph 23, the step of measuring whether the gene encoding the ALDH7A1 protein is methylated is to measure whether the methylation is methylated by a bisulfite sequencing method, a method for confirming whether the expression of the ALDH7A1 protein is inhibited.